Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON).

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03334617

Acronym

HUDSON

Enrollment

528

Registered

2017-11-07

Start date

2017-12-18

Completion date

2026-09-11

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Keywords

Non-small cell lung cancer, NSCLC, anti-PD-1/PD-L1, umbrella study, Durvalumab, MEDI4736, Olaparib, AZD2281, AZD9150, AZD6738, Vistusertib, AZD2014, Oleclumab, MEDI9447, Trastuzumab deruxtecan, DS-8201a, cediranib, AZD2171

Brief summary

This is an open-label, multi-centre, umbrella Phase II study in participants with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.

Detailed description

This is an open-label, multi-centre, umbrella Phase II study in participants with metastatic non-small cell lung cancer (NSCLC) who have progressed on an anti-programmed cell death-1/anti-programmed cell death ligand 1 (anti-PD-1/PD-L1) containing therapy. This study is modular in design, consisting of a number of treatment cohorts, allowing evaluation of the efficacy, safety, and tolerability of multiple treatment arms. There is currently no established therapy for participants who have received immune checkpoint inhibitors and platinum-doublet therapies, and novel treatments are urgently needed. This protocol has a modular design, with the potential for future treatment arms to be added via protocol amendment.

Interventions

DRUGTrastuzumab deruxtecan

Participants will receive IV infusion of trastuzumab deruxtecan as stated in arm description.

DRUGDurvalumab

Participants will receive IV infusion of durvalumab as stated in arm description.

DRUGDanvatirsen

Participants will receive IV infusion of danvatirsen as stated in arm description.

DRUGCeralasertib

Participants will receive oral tablet of ceralasertib as stated in arm description.

DRUGVistusertib

Participants will receive oral tablets of vistusertib as stated in arm description.

DRUGOlaparib

Participants will receive oral tablets of olaparib as stated in arm description.

DRUGOleclumab

Participants will receive IV infusion of oleclumab as stated in arm description.

DRUGCediranib

Participants will receive oral tablets of cediranib as stated in arm description.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* At least 18 years of age at the time of signing the informed consent form. * Participant must have histologically or cytologically confirmed metastatic or locally advanced and recurrent non-small-cell lung cancer (NSCLC) which is progressing. * Participants eligible for second- or later-line therapy, who must have received an anti-programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) containing therapy and a platinum-doublet regimen for locally advanced or metastatic NSCLC either separately or in combination. Prior durvalumab is acceptable. The participant must have had disease progression on a prior line of anti-PD-1/PD-L1 therapy. * Eastern Cooperative Oncology Group/World Health Organization (ECOG/WHO) performance status of 0 to 1, and a minimum life expectancy of 12 weeks. * Participant must have at least 1 lesion that can be accurately measured. A previously irradiated lesion can be considered a target lesion if the lesion has clearly progressed. * Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal participants.

Exclusion criteria

* Participants whose tumour samples have targetable alterations in epidermal growth factor receptor (EGFR) and/or anaplastic lymphoma kinase (ALK) at initial diagnosis are excluded. In addition, participants whose tumour samples are known to have targetable alterations in ROS1, BRAF, MET or RET, are to be excluded. * Active or prior documented autoimmune or inflammatory disorders. * Active infection including tuberculosis, hepatitis B (known positive hepatitis B virus \[HBV\] surface antigen \[HBsAg\] result), hepatitis C, or human immunodeficiency virus (positive human immunodeficiency virus \[HIV\] 1/2 antibodies). * Female participant who are pregnant or breastfeeding, or male or female participants of reproductive potential who are not willing to employ effective birth control. * Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients, or history of severe hypersensitivity reactions to other monoclonal antibodies. * Participant has spinal cord compression or symptomatic brain metastases. * Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. Participants may receive treatment with bisphosphonates or receptor activator of nuclear factor kappa-Β ligand (RANKL) inhibitors for the treatment of bone metastases. * History of active primary immunodeficiency.

Design outcomes

Primary

Measure	Time frame	Description
Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	Baseline (<=28 days before treatment), then every 6 weeks for 24 weeks from Cycle 1 Day 1, then every 8 weeks (every 9 weeks in Module 6) until disease progression or 90 days after study drug discontinuation (approximately 2 years)	Objective response was defined as participants with a confirmed investigator-assessed response complete response (CR) or partial response (PR) based on RECIST v 1.1. The CR is defined as disappearance of all target (TL) and non-target lesions (NTL), and any pathological lymph node (whether target or nontarget) must have reduction in short axis to \<10 mm. The PR is defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum diameters, as long as criteria for progressive disease (PD) are not met. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from date of first documentation. Percentage of participants with objective response was reported.

Secondary

Measure	Time frame	Description
Progression-Free Survival (PFS) Per RECIST v1.1	Every 3 months after safety follow-up visit (90 days after study drug discontinuation) until planned database lock for a module (either 12 months after last participant has started treatment or when 75% of participants died) (approximately up to 2 years)	The PFS is defined as time from first dose of any study drug until date of objective disease progression (PD) per RECIST v1.1 or death by any cause, regardless of whether the participant withdraws from study therapy or receives another anti-cancer therapy prior to progression. The PD is defined as a \>= 20% increase in the sum of diameters of TLs and an absolute increase of \>= 5mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters, or unequivocal progression of existing NTL. The PFS was analyzed using the Kaplan-Meier method
Best Percentage Change From Baseline in Tumour Size	Baseline (<=28 days prior to starting treatment) then every 6 weeks for first 24 weeks relative to the date of first dose/combination therapy (Cycle 1 Day 1), then every 8 weeks (except Module 6)/9 weeks (Module 6) thereafter (approximately up to 2 years)	The best percentage change in tumour size from baseline i.e. the maximum reduction from baseline or the minimum increase from baseline in absence of a reduction from baseline based on all post baseline assessments is reported. Tumour size is sum of the longest diameters (or short axis measurements for lymph nodes) of the target lesions. Baseline was defined as last evaluable assessment prior to starting treatment. The percentage change in target lesion tumour size at each week X for which data are available was obtained for each participant taking the difference between the sum of the target lesions at each week X and the sum of the target lesions at baseline divided by the sum of the target lesions at baseline multiplied by 100 (i.e. \[week X - baseline\]/baseline \* 100).
Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 and 24 weeks after the start of study drug	Module (M) 1, 4, 5, 6, 7, 8, 9, 11: DCR at 12 and 24 weeks is defined as percentage of participants who have best overall response (BoR) of CR or PR in first 13/25 weeks, respectively, post start of any study drug or with duration of SD for at least 11/23 weeks, respectively, after start of any study drug. M2, M3, M10: DCR at 12 and 24 weeks is defined as percentage of participants who have BoR of CR or PR within first 100 days (M2, M3, M10) or 184 days (M2, M3, M10) after start of any study drug, or have SD lasting at least 86 days (M2)/82 days (M3, M10), respectively, or 170 days (M2)/166 days (M3, M10), respectively, post start of any study drug. CR is defined as disappearance of all TL and NTLs, and any pathological lymph node (whether target or nontarget) must have reduction in short axis to \<10 mm. PR is defined as at least 30% decrease in sum of diameters of TLs, taking as reference baseline sum diameters, as long as criteria for PD are not met.
Duration of Response (DoR) Per RECIST v1.1	Baseline (<=28 days before treatment), then every 6 weeks for 24 weeks from Cycle 1 Day 1, then every 8 weeks (every 9 weeks in Module 6) until disease progression or 90 days after study drug discontinuation (approximately 2 years)	The DoR is defined as the time from the first documented confirmed response (CR or PR) until the first documented PD or death in the absence of disease progression. The CR is defined as disappearance of all TLs and NTLs, and any pathological lymph node (whether target or nontarget) must have reduction in short axis to \<10 mm. The PR is defined as at least a 30 decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters, as long as criteria for PD are not met. The PD is defined as a \>=20% increase in the sum of diameters of TLs and an absolute increase of \>=5mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters, or unequivocal progression of existing NTL. The DoR was analyzed using the Kaplan-Meier method.
Overall Survival (OS)	Every 3 months after safety follow-up visit (90 days after study drug discontinuation) until planned database lock for a module (either 12 months after last participant has started treatment or when 75% of participants died) (approximately up to 2 years)	The OS is defined as the time from the first dose of any study drug until death due to any cause regardless of whether the participant withdraws from study treatment or receives subsequent cancer therapy. The overall survival was analyzed using the Kaplan-Meier method.
Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Day 1 thorugh 58.6 months (maximum observed duration)	Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported. Abnormal clinical laboratory parameters defined as any abnormal finding during analysis of hematology, clinical chemistry, and urinalysis.
Number of Participants With Abnormal Vital Signs Reported as TEAEs	Day 1 thorugh 58.6 months (maximum observed duration)	Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal finding in the vital sign parameters (blood pressure, pulse rate, temperature, and respiration rate).
Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Day 1 thorugh 58.6 months (maximum observed duration)	Number of participants with abnormal physical examination findings reported as TEAEs are reported. Any new or aggravated clinically relevant abnormal medical finding at a physical examination as compared with the pre-dose assessment was reported as an AE.
Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Day 1 thorugh 58.6 months (maximum observed duration)	Number of participants with abnormal ECGs reported as TEAEs are reported.
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Day 1 thorugh 58.6 months (maximum observed duration)	An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

Countries

Austria, Canada, France, Germany, Israel, South Korea, Spain, United States

Participant flow

Recruitment details

The study was conducted at 45 centers in 8 countries (Austria, Canada, France, Germany, Israel, South Korea, Spain, and the United States).

Pre-assignment details

A total of 529 participants were enrolled in this study.

Participants by arm

Arm	Count
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg Participants with detectable aberrations, mutation detected in a homologous recombination repair gene (HRRm) received IV infusion of durvalumab 1500 mg every 4 weeks (Q4W) in combination with oral olaparib 300 mg (2 × 150 mg) tablets twice a day (BD) until disease progression is confirmed.	21
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg Participants with detectable aberrations in liver kinase B1 (LKB1) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed.	21
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg Participants who had anti-programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (primary resistance; PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed.	22
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg Participants who had progressive disease \> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (acquired resistance; ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral olaparib 300 mg (2 × 150 mg) tablets BD until disease progression is confirmed.	23
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.	23
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg Participants who had progressive disease \> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of AZD9150 (danvatirsen) 200 mg as loading dose on Days 1, 3, 5 of Cycle 0 (7-day-lead-in period). Thereafter, participants received AZD9150 200 mg every week (QW) on Days 1, 8, 15, and 22 of each 28-day cycle in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.	22
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg Participants who are ataxia telangiectasia mutated (ATM)-deficiecy received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD in each cycle between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria.	31
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria.	38
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg Participants who had progressive disease \> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received oral AZD6738 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral AZD6738 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria.	58
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg Participants with detectable genetic amplifications in rapamycin-insensitive companion of mechanistic target of rapamycin complex-2 (RICTOR) received IV infusion of durvalumab 1500 mg Q4W in combination with oral vistusertib 125 mg tablets BD on an intermittent dosing schedule of 2 days on, 5 days off, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria.	1
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg Participants with high expression of cluster of differentiation 73 (CD73) received IV infusion of oleclumab 3000 mg every 2 weeks (Q2W) for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.	23
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.	9
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg Participants who had progressive disease \> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of oleclumab 3000 mg Q2W for 2 cycles and then Q4W thereafter in combination with IV infusion of durvalumab 1500 mg Q4W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.	25
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg Participants whose tumours express human epidermal growth factor receptor 2 (HER2) mutations received IV infusion of trastuzumab deruxtecan (T-DXd) 5.4 mg/kg every 3 weeks (Q3W) in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.	23
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg Participants whose tumours harbour selected HER2 mutations received IV infusion of T-DXd 5.4 mg/kg Q3W in combination with IV infusion of durvalumab 1120 mg Q3W, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.	20
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg Participants who had progressive disease \> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W in combination with oral cediranib (AZD2171) 20 mg tablets daily for 5 days on, 2 days off (starting on Cycle 1 Day 1 of durvalumab), until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.	22
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg Participants who are ATM-deficient or with detectable aberrations in the ATM gene received oral ceralasertib (AZD6738) 240 mg tablets BD from Day 1 to Day 14 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.	15
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg Participants who had anti-PD-1/PD-L1 containing therapy but had progression of disease within ≤ 24 weeks from the start of treatment (PRI) received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.	19
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg Participants who had progressive disease \> 24 weeks from the start of anti PD-1/PD-L1 containing therapy while still on that treatment (ACQ) received IV infusion of durvalumab 1500 mg Q4W plus oral ceralasertib (AZD6738) 240 mg tablets BD for 14 days from Day 15 to Day 28 of each 28-day cycle, until objective radiological disease progression, as long as, in the investigator's opinion, they were benefiting from treatment and did not meet any other discontinuation criteria.	24
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 160 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 160 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria.	34
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg Participants, independent of their molecular aberration status, received oral ceralasertib (AZD6738) 240 mg tablet BD for 7 days in Cycle 0 (Days 1 to 7). Thereafter, participants received IV infusion of durvalumab 1500 mg Q4W in combination with oral ceralasertib 240 mg tablet BD between Days 22 and 28 in each 28-day cycle, until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria.	17
Module 11 Cohort C.11.240: AZD6738 240 mg Participants, independent of their molecular aberration status, received oral AZD6738 tablet 240 mg for 7 days (Days 1 to 7) in each 28-day cycle until objective radiological disease progression, however, participants may continue treatment if benefiting from treatment in the investigator opinion or did not meet any other discontinuation criteria.	38
Total	529

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004	FG005	FG006	FG007	FG008	FG010	FG011	FG012	FG013	FG014	FG015	FG016	FG017	FG018	FG019	FG020	FG021
Overall Study	Adverse Event	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	0	0	0	0
Overall Study	Continuing study off treatment at data cut-off	0	0	0	0	0	2	0	0	0	1	0	0	0	0	0	0	0	0	1	2	4
Overall Study	Death	18	18	20	21	20	16	28	35	47	19	6	20	22	17	18	12	15	16	27	14	27
Overall Study	Lost to Follow-up	0	0	0	1	0	1	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
Overall Study	Other	1	2	0	1	1	0	2	1	8	3	1	3	1	1	3	3	3	7	4	1	4
Overall Study	Withdrawal by Subject	0	1	0	0	1	1	1	2	0	0	1	1	0	2	1	0	1	1	1	0	1

Baseline characteristics

Characteristic	Total	Module 11 Cohort C.11.240: AZD6738 240 mg	Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg
Age, Continuous	63.0 Years STANDARD_DEVIATION 9.5	62.6 Years STANDARD_DEVIATION 8.4	64.1 Years STANDARD_DEVIATION 10.9	62.4 Years STANDARD_DEVIATION 8.4	59.9 Years STANDARD_DEVIATION 10.4	67.4 Years STANDARD_DEVIATION 11.5	61.1 Years STANDARD_DEVIATION 8.5	66.7 Years STANDARD_DEVIATION 8.2	65.8 Years STANDARD_DEVIATION 8.8	61.5 Years STANDARD_DEVIATION 12.8	62.7 Years STANDARD_DEVIATION 11.1	66.2 Years STANDARD_DEVIATION 8.6	61.9 Years STANDARD_DEVIATION 7.6	60.4 Years STANDARD_DEVIATION 10.2	NA Years	62.7 Years STANDARD_DEVIATION 9.4	62.2 Years STANDARD_DEVIATION 8.8	61.2 Years STANDARD_DEVIATION 8.2	64.1 Years STANDARD_DEVIATION 9.5	63.7 Years STANDARD_DEVIATION 9.8	66.5 Years STANDARD_DEVIATION 8.6	60.9 Years STANDARD_DEVIATION 7.6	60.2 Years STANDARD_DEVIATION 11.6
Ethnicity (NIH/OMB) Hispanic or Latino	4 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	2 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	511 Participants	38 Participants	17 Participants	34 Participants	21 Participants	24 Participants	19 Participants	15 Participants	21 Participants	19 Participants	21 Participants	23 Participants	9 Participants	22 Participants	0 Participants	55 Participants	36 Participants	29 Participants	22 Participants	21 Participants	23 Participants	22 Participants	20 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	14 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	2 Participants	0 Participants	0 Participants	1 Participants	3 Participants	2 Participants	2 Participants	0 Participants	2 Participants	0 Participants	0 Participants	1 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	87 Participants	5 Participants	3 Participants	6 Participants	4 Participants	4 Participants	4 Participants	1 Participants	3 Participants	4 Participants	5 Participants	7 Participants	0 Participants	1 Participants	0 Participants	6 Participants	8 Participants	0 Participants	6 Participants	1 Participants	11 Participants	8 Participants	0 Participants
Race (NIH/OMB) Black or African American	12 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	2 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	3 Participants	2 Participants	0 Participants	2 Participants	2 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	89 Participants	0 Participants	3 Participants	7 Participants	2 Participants	5 Participants	6 Participants	2 Participants	2 Participants	1 Participants	3 Participants	5 Participants	0 Participants	6 Participants	1 Participants	16 Participants	13 Participants	8 Participants	0 Participants	5 Participants	1 Participants	1 Participants	2 Participants
Race (NIH/OMB) White	340 Participants	33 Participants	11 Participants	21 Participants	15 Participants	15 Participants	9 Participants	12 Participants	16 Participants	13 Participants	15 Participants	13 Participants	9 Participants	15 Participants	0 Participants	33 Participants	15 Participants	23 Participants	14 Participants	15 Participants	11 Participants	13 Participants	19 Participants
Sex/Gender, Customized Female	198 Participants	13 Participants	4 Participants	9 Participants	8 Participants	10 Participants	5 Participants	5 Participants	5 Participants	11 Participants	8 Participants	9 Participants	7 Participants	11 Participants	0 Participants	17 Participants	10 Participants	15 Participants	11 Participants	11 Participants	8 Participants	12 Participants	9 Participants
Sex/Gender, Customized Male	330 Participants	25 Participants	13 Participants	25 Participants	13 Participants	14 Participants	14 Participants	10 Participants	17 Participants	9 Participants	15 Participants	16 Participants	2 Participants	12 Participants	0 Participants	41 Participants	28 Participants	16 Participants	11 Participants	12 Participants	15 Participants	10 Participants	12 Participants
Sex/Gender, Customized Other	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk	EG007 affected / at risk	EG008 affected / at risk	EG009 affected / at risk	EG010 affected / at risk	EG011 affected / at risk	EG012 affected / at risk	EG013 affected / at risk	EG014 affected / at risk	EG015 affected / at risk	EG016 affected / at risk	EG017 affected / at risk	EG018 affected / at risk	EG019 affected / at risk	EG020 affected / at risk	EG021 affected / at risk
deaths Total, all-cause mortality	18 / 21	18 / 21	20 / 22	21 / 23	21 / 23	16 / 22	28 / 31	35 / 38	48 / 58	0 / 1	19 / 23	6 / 9	21 / 25	22 / 23	17 / 20	18 / 22	13 / 15	15 / 19	17 / 24	27 / 34	14 / 17	27 / 38
other Total, other adverse events	19 / 21	19 / 21	19 / 22	21 / 23	22 / 23	19 / 22	30 / 31	34 / 38	55 / 58	1 / 1	19 / 23	5 / 9	22 / 25	23 / 23	20 / 20	20 / 22	15 / 15	17 / 19	24 / 24	30 / 34	16 / 17	38 / 38
serious Total, serious adverse events	10 / 21	7 / 21	8 / 22	7 / 23	12 / 23	8 / 22	11 / 31	11 / 38	17 / 58	0 / 1	7 / 23	1 / 9	6 / 25	10 / 23	10 / 20	7 / 22	7 / 15	7 / 19	13 / 24	12 / 34	1 / 17	17 / 38

Outcome results

Primary

Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)

Objective response was defined as participants with a confirmed investigator-assessed response complete response (CR) or partial response (PR) based on RECIST v 1.1. The CR is defined as disappearance of all target (TL) and non-target lesions (NTL), and any pathological lymph node (whether target or nontarget) must have reduction in short axis to \<10 mm. The PR is defined as at least a 30% decrease in the sum of the diameters of TLs, taking as reference the baseline sum diameters, as long as criteria for progressive disease (PD) are not met. Confirmation of CR and PR is required by a repeat, consecutive assessment no less than 4 weeks from date of first documentation. Percentage of participants with objective response was reported.

Time frame: Baseline (<=28 days before treatment), then every 6 weeks for 24 weeks from Cycle 1 Day 1, then every 8 weeks (every 9 weeks in Module 6) until disease progression or 90 days after study drug discontinuation (approximately 2 years)

Population: Evaluable for response population included all dosed participants who had measurable disease at baseline and who were analyzed according to their assigned cohort and planned treatment.

Arm	Measure	Value (NUMBER)
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	9.5 Percentage of Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	4.8 Percentage of Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	0 Percentage of Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	4.3 Percentage of Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	0 Percentage of Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	0 Percentage of Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	25.8 Percentage of Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	8.1 Percentage of Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	8.6 Percentage of Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	NA Percentage of Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	4.3 Percentage of Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	0 Percentage of Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	4.0 Percentage of Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	21.7 Percentage of Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	35.0 Percentage of Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	22.7 Percentage of Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	0 Percentage of Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	16.7 Percentage of Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	8.3 Percentage of Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	0 Percentage of Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	11.8 Percentage of Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)	2.6 Percentage of Participants

Secondary

Best Percentage Change From Baseline in Tumour Size

The best percentage change in tumour size from baseline i.e. the maximum reduction from baseline or the minimum increase from baseline in absence of a reduction from baseline based on all post baseline assessments is reported. Tumour size is sum of the longest diameters (or short axis measurements for lymph nodes) of the target lesions. Baseline was defined as last evaluable assessment prior to starting treatment. The percentage change in target lesion tumour size at each week X for which data are available was obtained for each participant taking the difference between the sum of the target lesions at each week X and the sum of the target lesions at baseline divided by the sum of the target lesions at baseline multiplied by 100 (i.e. \[week X - baseline\]/baseline \* 100).

Time frame: Baseline (<=28 days prior to starting treatment) then every 6 weeks for first 24 weeks relative to the date of first dose/combination therapy (Cycle 1 Day 1), then every 8 weeks (except Module 6)/9 weeks (Module 6) thereafter (approximately up to 2 years)

Population: Evaluable for response population included all dosed participants who had measurable disease at baseline and who were analyzed according to their assigned cohort and planned treatment. Number of participants analyzed (N) denotes the number of participants evaluated for this outcome measure.

Arm	Measure	Value (MEAN)	Dispersion
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Best Percentage Change From Baseline in Tumour Size	-0.79 Percent Change in Tumor Size	Standard Deviation 25.706
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Best Percentage Change From Baseline in Tumour Size	10.24 Percent Change in Tumor Size	Standard Deviation 25.197
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Best Percentage Change From Baseline in Tumour Size	7.19 Percent Change in Tumor Size	Standard Deviation 21.082
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Best Percentage Change From Baseline in Tumour Size	-3.55 Percent Change in Tumor Size	Standard Deviation 20.879
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Best Percentage Change From Baseline in Tumour Size	16.36 Percent Change in Tumor Size	Standard Deviation 20.732
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Best Percentage Change From Baseline in Tumour Size	3.06 Percent Change in Tumor Size	Standard Deviation 19.015
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Best Percentage Change From Baseline in Tumour Size	-10.12 Percent Change in Tumor Size	Standard Deviation 33.56
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Best Percentage Change From Baseline in Tumour Size	3.39 Percent Change in Tumor Size	Standard Deviation 29.846
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Best Percentage Change From Baseline in Tumour Size	-0.03 Percent Change in Tumor Size	Standard Deviation 29.952
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Best Percentage Change From Baseline in Tumour Size	NA Percent Change in Tumor Size	—
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Best Percentage Change From Baseline in Tumour Size	15.15 Percent Change in Tumor Size	Standard Deviation 24.412
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Best Percentage Change From Baseline in Tumour Size	19.55 Percent Change in Tumor Size	Standard Deviation 21.537
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Best Percentage Change From Baseline in Tumour Size	6.62 Percent Change in Tumor Size	Standard Deviation 29.231
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Best Percentage Change From Baseline in Tumour Size	-14.15 Percent Change in Tumor Size	Standard Deviation 35.815
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Best Percentage Change From Baseline in Tumour Size	-32.22 Percent Change in Tumor Size	Standard Deviation 35.655
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Best Percentage Change From Baseline in Tumour Size	-8.62 Percent Change in Tumor Size	Standard Deviation 38.546
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Best Percentage Change From Baseline in Tumour Size	-6.40 Percent Change in Tumor Size	Standard Deviation 17.207
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Best Percentage Change From Baseline in Tumour Size	8.96 Percent Change in Tumor Size	Standard Deviation 46.41
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Best Percentage Change From Baseline in Tumour Size	-2.59 Percent Change in Tumor Size	Standard Deviation 27.957
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Best Percentage Change From Baseline in Tumour Size	15.88 Percent Change in Tumor Size	Standard Deviation 34.908
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Best Percentage Change From Baseline in Tumour Size	19.74 Percent Change in Tumor Size	Standard Deviation 43.83
Module 11 Cohort C.11.240: AZD6738 240 mg	Best Percentage Change From Baseline in Tumour Size	-1.14 Percent Change in Tumor Size	Standard Deviation 22.354

Secondary

Duration of Response (DoR) Per RECIST v1.1

The DoR is defined as the time from the first documented confirmed response (CR or PR) until the first documented PD or death in the absence of disease progression. The CR is defined as disappearance of all TLs and NTLs, and any pathological lymph node (whether target or nontarget) must have reduction in short axis to \<10 mm. The PR is defined as at least a 30 decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters, as long as criteria for PD are not met. The PD is defined as a \>=20% increase in the sum of diameters of TLs and an absolute increase of \>=5mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters, or unequivocal progression of existing NTL. The DoR was analyzed using the Kaplan-Meier method.

Population: Evaluable for response population included all dosed participants who had measurable disease at baseline and who were analyzed according to their assigned cohort and planned treatment. The DoR was assessed for only those participants who had OR. Here, number of participants denotes those participants who had OR (confirmed CR or PR).

Arm	Measure	Value (MEDIAN)
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Duration of Response (DoR) Per RECIST v1.1	NA Months
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Duration of Response (DoR) Per RECIST v1.1	NA Months
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Duration of Response (DoR) Per RECIST v1.1	NA Months
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Duration of Response (DoR) Per RECIST v1.1	6.57 Months
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Duration of Response (DoR) Per RECIST v1.1	10.45 Months
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Duration of Response (DoR) Per RECIST v1.1	34.83 Months
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Duration of Response (DoR) Per RECIST v1.1	NA Months
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Duration of Response (DoR) Per RECIST v1.1	NA Months
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Duration of Response (DoR) Per RECIST v1.1	6.60 Months
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Duration of Response (DoR) Per RECIST v1.1	4.14 Months
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Duration of Response (DoR) Per RECIST v1.1	11.10 Months
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Duration of Response (DoR) Per RECIST v1.1	NA Months
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Duration of Response (DoR) Per RECIST v1.1	NA Months
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Duration of Response (DoR) Per RECIST v1.1	NA Months
Module 11 Cohort C.11.240: AZD6738 240 mg	Duration of Response (DoR) Per RECIST v1.1	NA Months

Secondary

Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs

Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported. Abnormal clinical laboratory parameters defined as any abnormal finding during analysis of hematology, clinical chemistry, and urinalysis.

Time frame: Day 1 thorugh 58.6 months (maximum observed duration)

Population: Safety analysis set included participants who received at least 1 dose of study drug and who were analyzed according to the actual treatment received and corresponding assigned cohort.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphocyte count decreased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulopathy	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time ratio increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hydronephrosis	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood bilirubin increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Brain natriuretic peptide increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulation time prolonged	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematocrit increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis	1 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Normocytic anaemia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haptoglobin increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Gamma-glutamyltransferase increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypomagnesaemia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis acute	1 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphadenopathy	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypertransaminasaemia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus decreased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal failure	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyponatraemia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count decreased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile bone marrow aplasia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Folate deficiency	1 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic enzyme increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood albumin decreased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thyroiditis	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride decreased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatinine increased	2 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Creatinine renal clearance decreased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Anaemia	7 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypernatraemia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile neutropenia	1 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophosphataemia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypothyroidism	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Azotaemia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Vitamin B12 deficiency	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphopenia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin T increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood alkaline phosphatase increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophysitis	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Eosinophil count increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Adrenal insufficiency	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cell count decreased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoalbuminaemia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood magnesium decreased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Cushingoid	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 2 diabetes mellitus	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypocalcaemia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercalcaemia	1 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	International normalised ratio increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pollakiuria	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood glucose increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	C-reactive protein increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood sodium decreased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count decreased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thrombin increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperlipasaemia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Leukopenia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen decreased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cells urine positive	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Iron deficiency	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperthyroidism	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thyroid stimulating hormone increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase decreased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood urea increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic cytolysis	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Protein total decreased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperkalaemia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count decreased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutropenia	1 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercholesterolaemia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Myocardial infarction	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatine phosphokinase increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematuria	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal disorder	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Proteinuria	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time prolonged	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood iron decreased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Liver function test increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoglycaemia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Amylase increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Procalcitonin increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Megakaryocytes abnormal	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypokalaemia	4 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thrombocytopenia	1 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperglycaemia	2 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium decreased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lipase increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatocellular injury	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haemoglobin decreased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Tri-iodothyronine increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancytopenia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Alanine aminotransferase increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Bilirubin conjugated increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Aspartate aminotransferase increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 1 diabetes mellitus	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperglycaemia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Liver function test increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperthyroidism	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase decreased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal disorder	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Amylase increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Megakaryocytes abnormal	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cells urine positive	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium decreased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperlipasaemia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoglycaemia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Protein total decreased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count decreased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatocellular injury	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase increased	1 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Tri-iodothyronine increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Leukopenia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen decreased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thyroid stimulating hormone increased	2 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Aspartate aminotransferase increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematuria	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood urea increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood iron decreased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time prolonged	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic enzyme increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatine phosphokinase increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypokalaemia	2 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lipase increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Myocardial infarction	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutropenia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile bone marrow aplasia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic cytolysis	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperkalaemia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Iron deficiency	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 1 diabetes mellitus	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count decreased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancytopenia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Alanine aminotransferase increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Procalcitonin increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercalcaemia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Proteinuria	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood sodium decreased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thrombocytopenia	1 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypernatraemia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Bilirubin conjugated increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haemoglobin decreased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis acute	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin T increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	C-reactive protein increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Azotaemia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride decreased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hydronephrosis	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thrombin increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	International normalised ratio increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Cushingoid	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulopathy	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile neutropenia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Creatinine renal clearance decreased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoalbuminaemia	1 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Adrenal insufficiency	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood magnesium decreased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Brain natriuretic peptide increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulation time prolonged	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thyroiditis	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Anaemia	7 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Normocytic anaemia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood bilirubin increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Gamma-glutamyltransferase increased	1 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophosphataemia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphocyte count decreased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematocrit increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercholesterolaemia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haptoglobin increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cell count decreased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time ratio increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypomagnesaemia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood glucose increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 2 diabetes mellitus	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus decreased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Vitamin B12 deficiency	1 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypertransaminasaemia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatinine increased	1 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyponatraemia	2 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal failure	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphopenia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophysitis	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count decreased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pollakiuria	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood alkaline phosphatase increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Eosinophil count increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Folate deficiency	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphadenopathy	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypocalcaemia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood albumin decreased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypothyroidism	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Anaemia	5 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Cushingoid	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal disorder	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulation time prolonged	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thyroiditis	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypertransaminasaemia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal failure	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count decreased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium increased	1 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematuria	1 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Folate deficiency	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphadenopathy	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride decreased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophosphataemia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Eosinophil count increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood alkaline phosphatase increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphopenia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood glucose increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase decreased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypocalcaemia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pollakiuria	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulopathy	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thrombin increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood bilirubin increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Azotaemia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Bilirubin conjugated increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphocyte count decreased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperlipasaemia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematocrit increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypomagnesaemia	1 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time prolonged	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Normocytic anaemia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haptoglobin increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	C-reactive protein increased	1 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cells urine positive	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hydronephrosis	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count decreased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin T increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercholesterolaemia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 2 diabetes mellitus	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophysitis	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatinine increased	3 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood albumin decreased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyponatraemia	1 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus decreased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time ratio increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cell count decreased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Myocardial infarction	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood sodium decreased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Procalcitonin increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperkalaemia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile neutropenia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Vitamin B12 deficiency	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancytopenia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	International normalised ratio increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 1 diabetes mellitus	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium decreased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Protein total decreased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Liver function test increased	1 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Leukopenia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypernatraemia	1 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen decreased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis acute	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile bone marrow aplasia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypothyroidism	1 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Alanine aminotransferase increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercalcaemia	1 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoalbuminaemia	1 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Brain natriuretic peptide increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperthyroidism	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatocellular injury	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thrombocytopenia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Creatinine renal clearance decreased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Gamma-glutamyltransferase increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatine phosphokinase increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Tri-iodothyronine increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic enzyme increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Megakaryocytes abnormal	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Proteinuria	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Aspartate aminotransferase increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lipase increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoglycaemia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood urea increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperglycaemia	1 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood iron decreased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haemoglobin decreased	1 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Adrenal insufficiency	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thyroid stimulating hormone increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Amylase increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Iron deficiency	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count decreased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic cytolysis	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutropenia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood magnesium decreased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypokalaemia	1 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic cytolysis	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	International normalised ratio increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count decreased	1 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercalcaemia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Megakaryocytes abnormal	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypokalaemia	1 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoalbuminaemia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Vitamin B12 deficiency	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time ratio increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Adrenal insufficiency	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Tri-iodothyronine increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Creatinine renal clearance decreased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium decreased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperkalaemia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood magnesium decreased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thyroid stimulating hormone increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood sodium decreased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 1 diabetes mellitus	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Alanine aminotransferase increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypothyroidism	2 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile bone marrow aplasia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypernatraemia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Iron deficiency	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis acute	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Brain natriuretic peptide increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoglycaemia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Amylase increased	1 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulation time prolonged	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Liver function test increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haemoglobin decreased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Procalcitonin increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile neutropenia	1 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperglycaemia	1 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Aspartate aminotransferase increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutropenia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancytopenia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Myocardial infarction	1 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatine phosphokinase increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic enzyme increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood urea increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lipase increased	1 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thrombocytopenia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Leukopenia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatocellular injury	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Proteinuria	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood iron decreased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Gamma-glutamyltransferase increased	1 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase decreased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus decreased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cells urine positive	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal failure	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hydronephrosis	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pollakiuria	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypocalcaemia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count decreased	1 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperthyroidism	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood glucose increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin T increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen decreased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cell count decreased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Cushingoid	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 2 diabetes mellitus	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercholesterolaemia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride decreased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood alkaline phosphatase increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood bilirubin increased	1 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphopenia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophysitis	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood albumin decreased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatinine increased	1 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thyroiditis	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Eosinophil count increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphadenopathy	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal disorder	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Folate deficiency	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophosphataemia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Protein total decreased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematuria	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyponatraemia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypomagnesaemia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematocrit increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperlipasaemia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time prolonged	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Bilirubin conjugated increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Anaemia	7 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Normocytic anaemia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphocyte count decreased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Azotaemia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count decreased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haptoglobin increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thrombin increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulopathy	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	C-reactive protein increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypertransaminasaemia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time prolonged	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphadenopathy	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypothyroidism	2 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood bilirubin increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count decreased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophosphataemia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Adrenal insufficiency	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphopenia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Creatinine renal clearance decreased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count increased	1 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood alkaline phosphatase increased	1 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride decreased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypocalcaemia	2 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Gamma-glutamyltransferase increased	1 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematocrit increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphocyte count decreased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase decreased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypomagnesaemia	1 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	C-reactive protein increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count decreased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin T increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatinine increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyponatraemia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus decreased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Anaemia	4 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancytopenia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 2 diabetes mellitus	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count increased	1 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thyroiditis	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal disorder	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypertransaminasaemia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cells urine positive	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cell count decreased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Protein total decreased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis acute	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood albumin decreased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophysitis	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercholesterolaemia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hydronephrosis	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Megakaryocytes abnormal	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haptoglobin increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Normocytic anaemia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thrombin increased	1 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pollakiuria	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood glucose increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen decreased	1 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Eosinophil count increased	1 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Folate deficiency	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Cushingoid	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematuria	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic enzyme increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Proteinuria	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count increased	1 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Alanine aminotransferase increased	3 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood urea increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperglycaemia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulopathy	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium decreased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Aspartate aminotransferase increased	2 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercalcaemia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Myocardial infarction	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperthyroidism	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Iron deficiency	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Vitamin B12 deficiency	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Bilirubin conjugated increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood iron decreased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	International normalised ratio increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Leukopenia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood magnesium decreased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 1 diabetes mellitus	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile neutropenia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperkalaemia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoalbuminaemia	1 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lipase increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thyroid stimulating hormone increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Amylase increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Azotaemia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood sodium decreased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperlipasaemia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoglycaemia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile bone marrow aplasia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypokalaemia	2 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Brain natriuretic peptide increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal failure	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypernatraemia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thrombocytopenia	4 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutropenia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatocellular injury	1 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulation time prolonged	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Procalcitonin increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haemoglobin decreased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic cytolysis	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatine phosphokinase increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Tri-iodothyronine increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time ratio increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Liver function test increased	3 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count decreased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood iron decreased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypokalaemia	1 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Liver function test increased	1 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperlipasaemia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lipase increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile bone marrow aplasia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypernatraemia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile neutropenia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hydronephrosis	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperglycaemia	1 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thyroid stimulating hormone increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thrombocytopenia	6 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Tri-iodothyronine increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Alanine aminotransferase increased	5 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Proteinuria	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutropenia	1 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Normocytic anaemia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematocrit increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count decreased	1 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic cytolysis	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulation time prolonged	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time ratio increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Azotaemia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Aspartate aminotransferase increased	3 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Vitamin B12 deficiency	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperkalaemia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 1 diabetes mellitus	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Iron deficiency	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic enzyme increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood urea increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercalcaemia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperthyroidism	1 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	International normalised ratio increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Bilirubin conjugated increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Leukopenia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulopathy	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoalbuminaemia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium decreased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatocellular injury	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Amylase increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoglycaemia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Brain natriuretic peptide increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haemoglobin decreased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal failure	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood bilirubin increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood sodium decreased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Procalcitonin increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphadenopathy	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood alkaline phosphatase increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Eosinophil count increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride decreased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyponatraemia	1 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatine phosphokinase increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Gamma-glutamyltransferase increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pollakiuria	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Myocardial infarction	1 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphopenia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood magnesium decreased	1 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thrombin increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen decreased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood glucose increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypocalcaemia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 2 diabetes mellitus	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatinine increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood albumin decreased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cells urine positive	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophysitis	1 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypothyroidism	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count decreased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercholesterolaemia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin T increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count decreased	2 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cell count decreased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematuria	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Megakaryocytes abnormal	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Anaemia	4 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal disorder	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	C-reactive protein increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Cushingoid	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haptoglobin increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancytopenia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypertransaminasaemia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase decreased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time prolonged	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis acute	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypomagnesaemia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thyroiditis	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophosphataemia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphocyte count decreased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Folate deficiency	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus decreased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Adrenal insufficiency	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Protein total decreased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Creatinine renal clearance decreased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercholesterolaemia	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Folate deficiency	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus decreased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Eosinophil count increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatine phosphokinase increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematuria	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophosphataemia	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thrombin increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride decreased	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count decreased	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Azotaemia	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphopenia	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Gamma-glutamyltransferase increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis acute	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time prolonged	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pollakiuria	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Megakaryocytes abnormal	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Myocardial infarction	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Proteinuria	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood magnesium decreased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperthyroidism	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyponatraemia	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood glucose increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen decreased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypertransaminasaemia	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypocalcaemia	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Anaemia	10 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperlipasaemia	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count decreased	2 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haptoglobin increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood albumin decreased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 2 diabetes mellitus	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal disorder	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Iron deficiency	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	C-reactive protein increased	2 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancytopenia	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophysitis	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulation time prolonged	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Protein total decreased	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatinine increased	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphocyte count decreased	2 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Cushingoid	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cell count decreased	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic cytolysis	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Aspartate aminotransferase increased	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile bone marrow aplasia	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypokalaemia	2 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Adrenal insufficiency	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Creatinine renal clearance decreased	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperkalaemia	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Vitamin B12 deficiency	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time ratio increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematocrit increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Tri-iodothyronine increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hydronephrosis	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood bilirubin increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Procalcitonin increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypothyroidism	2 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Amylase increased	2 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thyroiditis	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin T increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Liver function test increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile neutropenia	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cells urine positive	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutropenia	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic enzyme increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood alkaline phosphatase increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Leukopenia	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatocellular injury	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercalcaemia	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood iron decreased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	International normalised ratio increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Normocytic anaemia	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count decreased	2 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lipase increased	3 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood urea increased	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Brain natriuretic peptide increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperglycaemia	2 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoglycaemia	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haemoglobin decreased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal failure	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood sodium decreased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypomagnesaemia	2 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypernatraemia	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thyroid stimulating hormone increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase decreased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thrombocytopenia	4 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Alanine aminotransferase increased	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphadenopathy	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 1 diabetes mellitus	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoalbuminaemia	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Bilirubin conjugated increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulopathy	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium decreased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride decreased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 1 diabetes mellitus	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulopathy	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood urea increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypernatraemia	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hydronephrosis	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Aspartate aminotransferase increased	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperkalaemia	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Alanine aminotransferase increased	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatocellular injury	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulation time prolonged	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count decreased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphadenopathy	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercholesterolaemia	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Tri-iodothyronine increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cells urine positive	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time ratio increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutropenia	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematocrit increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Leukopenia	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood albumin decreased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Brain natriuretic peptide increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercalcaemia	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperglycaemia	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood alkaline phosphatase increased	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pollakiuria	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypothyroidism	2 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile neutropenia	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Normocytic anaemia	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lipase increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Liver function test increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Bilirubin conjugated increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium decreased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin T increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Amylase increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypokalaemia	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cell count decreased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thyroiditis	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haemoglobin decreased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic cytolysis	2 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal failure	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood iron decreased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Adrenal insufficiency	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Creatinine renal clearance decreased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoalbuminaemia	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	International normalised ratio increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypomagnesaemia	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis acute	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic enzyme increased	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thyroid stimulating hormone increased	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood bilirubin increased	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	C-reactive protein increased	2 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Anaemia	9 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypertransaminasaemia	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count decreased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thrombocytopenia	2 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus decreased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Proteinuria	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyponatraemia	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Iron deficiency	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophysitis	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoglycaemia	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatinine increased	2 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count decreased	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Megakaryocytes abnormal	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase decreased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haptoglobin increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Protein total decreased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Procalcitonin increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Azotaemia	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time prolonged	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperlipasaemia	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Folate deficiency	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile bone marrow aplasia	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thrombin increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase increased	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphocyte count decreased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood sodium decreased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood magnesium decreased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Gamma-glutamyltransferase increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood glucose increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen decreased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypocalcaemia	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Vitamin B12 deficiency	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Eosinophil count increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Myocardial infarction	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophosphataemia	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Cushingoid	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperthyroidism	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatine phosphokinase increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematuria	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 2 diabetes mellitus	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphopenia	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal disorder	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancytopenia	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphocyte count decreased	2 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Adrenal insufficiency	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancytopenia	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thrombin increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 2 diabetes mellitus	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Myocardial infarction	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus decreased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile bone marrow aplasia	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	C-reactive protein increased	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypertransaminasaemia	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophosphataemia	5 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal disorder	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Procalcitonin increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haptoglobin increased	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 1 diabetes mellitus	2 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase decreased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time prolonged	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count decreased	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Megakaryocytes abnormal	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatinine increased	2 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoglycaemia	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophysitis	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin T increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematuria	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Iron deficiency	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypothyroidism	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thrombocytopenia	4 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyponatraemia	7 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis acute	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count decreased	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Anaemia	19 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatine phosphokinase increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Protein total decreased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphopenia	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count increased	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen decreased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Gamma-glutamyltransferase increased	2 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen increased	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood magnesium decreased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Azotaemia	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Vitamin B12 deficiency	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Proteinuria	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lipase increased	2 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood sodium decreased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Bilirubin conjugated increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Eosinophil count increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pollakiuria	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile neutropenia	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hydronephrosis	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium decreased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Normocytic anaemia	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypernatraemia	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	International normalised ratio increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypomagnesaemia	3 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood glucose increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatocellular injury	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Liver function test increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperlipasaemia	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cells urine positive	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Alanine aminotransferase increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal failure	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoalbuminaemia	2 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulation time prolonged	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood alkaline phosphatase increased	4 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercalcaemia	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thyroid stimulating hormone increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypokalaemia	5 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphadenopathy	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thyroiditis	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood bilirubin increased	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride decreased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic cytolysis	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Tri-iodothyronine increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cell count decreased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Cushingoid	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time ratio increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood iron decreased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematocrit increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperthyroidism	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Leukopenia	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Folate deficiency	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Brain natriuretic peptide increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutropenia	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count decreased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Creatinine renal clearance decreased	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Aspartate aminotransferase increased	3 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperkalaemia	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypocalcaemia	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haemoglobin decreased	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulopathy	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercholesterolaemia	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood albumin decreased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperglycaemia	2 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic enzyme increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Amylase increased	2 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood urea increased	1 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypokalaemia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercalcaemia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Leukopenia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypocalcaemia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pollakiuria	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood alkaline phosphatase increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatocellular injury	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cells urine positive	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic enzyme increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Brain natriuretic peptide increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Creatinine renal clearance decreased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutropenia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperglycaemia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulopathy	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercholesterolaemia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile neutropenia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Liver function test increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 2 diabetes mellitus	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematuria	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haemoglobin decreased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Amylase increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal failure	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood glucose increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypomagnesaemia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Tri-iodothyronine increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Procalcitonin increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperlipasaemia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hydronephrosis	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypernatraemia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Alanine aminotransferase increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood bilirubin increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase decreased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile bone marrow aplasia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphadenopathy	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematocrit increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time ratio increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Cushingoid	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoalbuminaemia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperkalaemia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Aspartate aminotransferase increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperthyroidism	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium decreased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic cytolysis	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Normocytic anaemia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thyroid stimulating hormone increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	International normalised ratio increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood iron decreased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphocyte count decreased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood albumin decreased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Megakaryocytes abnormal	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time prolonged	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypothyroidism	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Adrenal insufficiency	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Vitamin B12 deficiency	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Azotaemia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride decreased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen decreased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood magnesium decreased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haptoglobin increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis acute	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cell count decreased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thyroiditis	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoglycaemia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus decreased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancytopenia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatine phosphokinase increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypertransaminasaemia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Proteinuria	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Myocardial infarction	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Eosinophil count increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood urea increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 1 diabetes mellitus	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Bilirubin conjugated increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Folate deficiency	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood sodium decreased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thrombin increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophysitis	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Iron deficiency	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Protein total decreased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal disorder	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin T increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulation time prolonged	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Anaemia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thrombocytopenia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyponatraemia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatinine increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count decreased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	C-reactive protein increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lipase increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count decreased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Gamma-glutamyltransferase increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophosphataemia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count decreased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphopenia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoglycaemia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium decreased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Protein total decreased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen decreased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatinine increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus decreased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Cushingoid	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphopenia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypertransaminasaemia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Eosinophil count increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyponatraemia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count decreased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Myocardial infarction	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cell count decreased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatine phosphokinase increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	C-reactive protein increased	1 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulation time prolonged	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Megakaryocytes abnormal	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood urea increased	1 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time prolonged	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis acute	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Bilirubin conjugated increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal disorder	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haptoglobin increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thrombin increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thrombocytopenia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphocyte count decreased	1 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Iron deficiency	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophosphataemia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood albumin decreased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride decreased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood magnesium decreased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood sodium decreased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lipase increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypothyroidism	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count decreased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancytopenia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Vitamin B12 deficiency	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Gamma-glutamyltransferase increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Proteinuria	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Anaemia	1 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypocalcaemia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin T increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophysitis	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count decreased	1 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Azotaemia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 1 diabetes mellitus	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pollakiuria	1 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypernatraemia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hydronephrosis	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperkalaemia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoalbuminaemia	1 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic cytolysis	1 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood glucose increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypomagnesaemia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Tri-iodothyronine increased	1 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood alkaline phosphatase increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Procalcitonin increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Adrenal insufficiency	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal failure	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic enzyme increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Amylase increased	1 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperthyroidism	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haemoglobin decreased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Brain natriuretic peptide increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood iron decreased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematuria	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulopathy	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperlipasaemia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thyroiditis	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Leukopenia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 2 diabetes mellitus	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutropenia	1 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Liver function test increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercholesterolaemia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cells urine positive	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Normocytic anaemia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile neutropenia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Creatinine renal clearance decreased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperglycaemia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thyroid stimulating hormone increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypokalaemia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercalcaemia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Folate deficiency	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematocrit increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatocellular injury	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	International normalised ratio increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time ratio increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase decreased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood bilirubin increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphadenopathy	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile bone marrow aplasia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Alanine aminotransferase increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Aspartate aminotransferase increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Leukopenia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cells urine positive	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypothyroidism	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematuria	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thyroid stimulating hormone increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperthyroidism	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Adrenal insufficiency	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride decreased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood bilirubin increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Folate deficiency	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematocrit increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haptoglobin increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Amylase increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time ratio increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thyroiditis	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count decreased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutropenia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Liver function test increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile neutropenia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood alkaline phosphatase increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic enzyme increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercalcaemia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood iron decreased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Gamma-glutamyltransferase increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Normocytic anaemia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic cytolysis	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperglycaemia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Creatinine renal clearance decreased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypomagnesaemia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haemoglobin decreased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal failure	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Alanine aminotransferase increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypernatraemia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphadenopathy	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase decreased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoalbuminaemia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulopathy	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium decreased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile bone marrow aplasia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	International normalised ratio increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypokalaemia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood glucose increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyponatraemia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Brain natriuretic peptide increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatocellular injury	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercholesterolaemia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 2 diabetes mellitus	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Tri-iodothyronine increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Procalcitonin increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Cushingoid	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood magnesium decreased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Myocardial infarction	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count decreased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen decreased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatine phosphokinase increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancytopenia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Anaemia	1 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Protein total decreased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin T increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal disorder	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus decreased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Proteinuria	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperkalaemia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Aspartate aminotransferase increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Azotaemia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Iron deficiency	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Bilirubin conjugated increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood albumin decreased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time prolonged	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypocalcaemia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophysitis	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoglycaemia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphopenia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pollakiuria	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulation time prolonged	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperlipasaemia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatinine increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Eosinophil count increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 1 diabetes mellitus	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hydronephrosis	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Megakaryocytes abnormal	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count decreased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cell count decreased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis acute	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood urea increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	C-reactive protein increased	1 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thrombocytopenia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thrombin increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophosphataemia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphocyte count decreased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood sodium decreased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypertransaminasaemia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lipase increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Vitamin B12 deficiency	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Folate deficiency	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal disorder	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 1 diabetes mellitus	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulation time prolonged	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatine phosphokinase increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancytopenia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin T increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperkalaemia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Bilirubin conjugated increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypocalcaemia	2 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperthyroidism	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood urea increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophosphataemia	1 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Vitamin B12 deficiency	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Eosinophil count increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen decreased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count decreased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Myocardial infarction	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood magnesium decreased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lipase increased	1 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphocyte count decreased	2 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood sodium decreased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulopathy	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Cushingoid	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thrombin increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	C-reactive protein increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count decreased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphopenia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Megakaryocytes abnormal	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hydronephrosis	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatinine increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperlipasaemia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoglycaemia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophysitis	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood albumin decreased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Aspartate aminotransferase increased	1 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Iron deficiency	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Azotaemia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis acute	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Proteinuria	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Protein total decreased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypertransaminasaemia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thrombocytopenia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus decreased	1 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Anaemia	3 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic enzyme increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile bone marrow aplasia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase decreased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium decreased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoalbuminaemia	2 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypothyroidism	1 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphadenopathy	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyponatraemia	1 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cells urine positive	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypernatraemia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Alanine aminotransferase increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal failure	1 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haemoglobin decreased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypomagnesaemia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Creatinine renal clearance decreased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperglycaemia	1 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Brain natriuretic peptide increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time prolonged	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pollakiuria	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic cytolysis	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Gamma-glutamyltransferase increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood iron decreased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercalcaemia	2 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Leukopenia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thyroiditis	1 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood alkaline phosphatase increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatocellular injury	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile neutropenia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time ratio increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercholesterolaemia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Liver function test increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutropenia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 2 diabetes mellitus	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Procalcitonin increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count decreased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Tri-iodothyronine increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cell count decreased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Amylase increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haptoglobin increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematocrit increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood bilirubin increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride decreased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Adrenal insufficiency	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematuria	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thyroid stimulating hormone increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypokalaemia	1 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	International normalised ratio increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood glucose increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Normocytic anaemia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium decreased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Amylase increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulopathy	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatocellular injury	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time prolonged	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoalbuminaemia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphadenopathy	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood alkaline phosphatase increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Normocytic anaemia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypocalcaemia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyponatraemia	2 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile neutropenia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haptoglobin increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Liver function test increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypernatraemia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thyroiditis	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Alanine aminotransferase increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal failure	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercholesterolaemia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypothyroidism	1 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood bilirubin increased	2 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypomagnesaemia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Creatinine renal clearance decreased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutropenia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 2 diabetes mellitus	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperglycaemia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pollakiuria	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cells urine positive	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile bone marrow aplasia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Brain natriuretic peptide increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypokalaemia	3 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count decreased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Tri-iodothyronine increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Gamma-glutamyltransferase increased	1 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Anaemia	7 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	International normalised ratio increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood iron decreased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Adrenal insufficiency	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cell count decreased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercalcaemia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Leukopenia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood glucose increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Procalcitonin increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic enzyme increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematuria	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time ratio increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperkalaemia	2 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus decreased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Bilirubin conjugated increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Iron deficiency	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haemoglobin decreased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	C-reactive protein increased	1 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood urea increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis acute	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphopenia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Proteinuria	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancytopenia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen decreased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophosphataemia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin T increased	1 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood sodium decreased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thyroid stimulating hormone increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematocrit increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride decreased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count decreased	1 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal disorder	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Myocardial infarction	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Protein total decreased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood magnesium decreased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Vitamin B12 deficiency	1 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lipase increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count decreased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphocyte count decreased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase increased	1 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypertransaminasaemia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Megakaryocytes abnormal	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Eosinophil count increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatine phosphokinase increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hydronephrosis	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thrombocytopenia	1 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Cushingoid	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatinine increased	1 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase decreased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperthyroidism	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Azotaemia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperlipasaemia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thrombin increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 1 diabetes mellitus	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoglycaemia	1 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Folate deficiency	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophysitis	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood albumin decreased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Aspartate aminotransferase increased	1 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic cytolysis	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulation time prolonged	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cell count decreased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time prolonged	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thyroid stimulating hormone increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Folate deficiency	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lipase increased	3 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Liver function test increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count decreased	4 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic cytolysis	2 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Bilirubin conjugated increased	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypertransaminasaemia	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Aspartate aminotransferase increased	3 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase increased	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulation time prolonged	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutropenia	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Iron deficiency	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase decreased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperlipasaemia	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haemoglobin decreased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Vitamin B12 deficiency	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	C-reactive protein increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thrombocytopenia	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancytopenia	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperthyroidism	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Tri-iodothyronine increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Megakaryocytes abnormal	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis acute	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperkalaemia	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Proteinuria	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus decreased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal disorder	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thrombin increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin T increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Eosinophil count increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulopathy	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophysitis	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood albumin decreased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hydronephrosis	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatine phosphokinase increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen decreased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride decreased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Cushingoid	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood iron decreased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatinine increased	3 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoglycaemia	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematocrit increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Azotaemia	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood sodium decreased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Myocardial infarction	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count decreased	4 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count increased	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 1 diabetes mellitus	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophosphataemia	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood urea increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphopenia	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Protein total decreased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic enzyme increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood magnesium decreased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Leukopenia	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypothyroidism	2 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematuria	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Adrenal insufficiency	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haptoglobin increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile neutropenia	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count increased	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	International normalised ratio increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Normocytic anaemia	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pollakiuria	2 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Creatinine renal clearance decreased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal failure	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypernatraemia	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin increased	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphadenopathy	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium decreased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile bone marrow aplasia	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood glucose increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Brain natriuretic peptide increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatocellular injury	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercholesterolaemia	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Procalcitonin increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time ratio increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cells urine positive	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thyroiditis	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 2 diabetes mellitus	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Anaemia	12 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyponatraemia	5 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypokalaemia	2 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoalbuminaemia	5 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Alanine aminotransferase increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypomagnesaemia	2 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperglycaemia	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphocyte count decreased	3 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Gamma-glutamyltransferase increased	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercalcaemia	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood alkaline phosphatase increased	3 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count decreased	4 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Amylase increased	2 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypocalcaemia	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood bilirubin increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haptoglobin increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphadenopathy	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal failure	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypocalcaemia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood alkaline phosphatase increased	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Anaemia	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Leukopenia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 2 diabetes mellitus	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cells urine positive	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time ratio increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood glucose increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood albumin decreased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Alanine aminotransferase increased	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	International normalised ratio increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Amylase increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood bilirubin increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin T increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypernatraemia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypokalaemia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercholesterolaemia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoalbuminaemia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Gamma-glutamyltransferase increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypothyroidism	3 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Normocytic anaemia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Brain natriuretic peptide increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count decreased	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lipase increased	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatocellular injury	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile neutropenia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile bone marrow aplasia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pollakiuria	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophysitis	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulation time prolonged	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium decreased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphocyte count decreased	2 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Creatinine renal clearance decreased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Procalcitonin increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulopathy	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyponatraemia	2 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypomagnesaemia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen decreased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood sodium decreased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thrombocytopenia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Folate deficiency	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thrombin increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperglycaemia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Eosinophil count increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	C-reactive protein increased	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypertransaminasaemia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time prolonged	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematocrit increased	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophosphataemia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cell count decreased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count decreased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperkalaemia	2 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Megakaryocytes abnormal	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutropenia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thyroiditis	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Tri-iodothyronine increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Cushingoid	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hydronephrosis	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatinine increased	2 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood urea increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Azotaemia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase decreased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus decreased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperlipasaemia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematuria	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic cytolysis	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoglycaemia	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Aspartate aminotransferase increased	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thyroid stimulating hormone increased	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood iron decreased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Bilirubin conjugated increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Iron deficiency	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haemoglobin decreased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancytopenia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Liver function test increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatine phosphokinase increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Proteinuria	2 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal disorder	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis acute	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Adrenal insufficiency	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercalcaemia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Protein total decreased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic enzyme increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Myocardial infarction	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count decreased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Vitamin B12 deficiency	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride decreased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood magnesium decreased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 1 diabetes mellitus	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperthyroidism	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphopenia	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal disorder	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Vitamin B12 deficiency	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Azotaemia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haemoglobin decreased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematuria	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood urea increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Cushingoid	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Eosinophil count increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Folate deficiency	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride decreased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Adrenal insufficiency	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Myocardial infarction	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood magnesium decreased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thrombin increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time prolonged	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematocrit increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Megakaryocytes abnormal	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hydronephrosis	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase decreased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperlipasaemia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood iron decreased	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Iron deficiency	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Proteinuria	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypertransaminasaemia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cell count decreased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatine phosphokinase increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancytopenia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus decreased	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thrombocytopenia	3 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Liver function test increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Aspartate aminotransferase increased	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoglycaemia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatinine increased	2 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Tri-iodothyronine increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thyroiditis	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count decreased	4 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	C-reactive protein increased	2 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperglycaemia	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood sodium decreased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen decreased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercalcaemia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count decreased	2 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 1 diabetes mellitus	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperthyroidism	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutropenia	2 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Amylase increased	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypothyroidism	2 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperkalaemia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Bilirubin conjugated increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile bone marrow aplasia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphocyte count decreased	2 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium decreased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulopathy	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Creatinine renal clearance decreased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypomagnesaemia	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pollakiuria	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal failure	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulation time prolonged	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Alanine aminotransferase increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoalbuminaemia	2 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypernatraemia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphadenopathy	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 2 diabetes mellitus	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood bilirubin increased	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercholesterolaemia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatocellular injury	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time ratio increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haptoglobin increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Procalcitonin increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypocalcaemia	2 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Anaemia	12 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis acute	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thyroid stimulating hormone increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Protein total decreased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count decreased	2 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophysitis	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Brain natriuretic peptide increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin T increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile neutropenia	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyponatraemia	2 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cells urine positive	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count increased	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophosphataemia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood alkaline phosphatase increased	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic enzyme increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Leukopenia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood glucose increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood albumin decreased	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	International normalised ratio increased	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphopenia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Gamma-glutamyltransferase increased	2 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypokalaemia	3 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Normocytic anaemia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lipase increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic cytolysis	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis acute	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophysitis	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercholesterolaemia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 2 diabetes mellitus	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulation time prolonged	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Anaemia	8 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Brain natriuretic peptide increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyponatraemia	2 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood glucose increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypokalaemia	2 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile bone marrow aplasia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium decreased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulopathy	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoalbuminaemia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphadenopathy	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypernatraemia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pollakiuria	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Alanine aminotransferase increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal failure	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypomagnesaemia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Eosinophil count increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Creatinine renal clearance decreased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic cytolysis	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphocyte count decreased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Adrenal insufficiency	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lipase increased	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Normocytic anaemia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	International normalised ratio increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood albumin decreased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic enzyme increased	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood alkaline phosphatase increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophosphataemia	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile neutropenia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoglycaemia	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count decreased	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thyroiditis	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Protein total decreased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypocalcaemia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Procalcitonin increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thyroid stimulating hormone increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood bilirubin increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphopenia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cells urine positive	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thrombocytopenia	5 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperglycaemia	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haptoglobin increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thrombin increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Gamma-glutamyltransferase increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen decreased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haemoglobin decreased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Myocardial infarction	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood magnesium decreased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood sodium decreased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatine phosphokinase increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Liver function test increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Leukopenia	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Bilirubin conjugated increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal disorder	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Iron deficiency	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Proteinuria	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood iron decreased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Aspartate aminotransferase increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperkalaemia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin T increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Amylase increased	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Vitamin B12 deficiency	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematuria	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood urea increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperlipasaemia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase decreased	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hydronephrosis	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutropenia	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatinine increased	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Cushingoid	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Tri-iodothyronine increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cell count decreased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus decreased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Folate deficiency	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypertransaminasaemia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatocellular injury	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Megakaryocytes abnormal	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count decreased	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperthyroidism	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 1 diabetes mellitus	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematocrit increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time ratio increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time prolonged	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride decreased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count decreased	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypothyroidism	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Azotaemia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	C-reactive protein increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancytopenia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercalcaemia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperthyroidism	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase decreased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatine phosphokinase increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutropenia	2 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hydronephrosis	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Leukopenia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thrombin increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count decreased	2 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperglycaemia	2 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haemoglobin decreased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Gamma-glutamyltransferase increased	2 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haptoglobin increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thrombocytopenia	10 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatinine increased	2 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cell count decreased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Vitamin B12 deficiency	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypothyroidism	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematocrit increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Myocardial infarction	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	C-reactive protein increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time ratio increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperkalaemia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood sodium decreased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Cushingoid	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase increased	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen decreased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood alkaline phosphatase increased	2 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood magnesium decreased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Liver function test increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Procalcitonin increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin T increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Folate deficiency	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypertransaminasaemia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Iron deficiency	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatocellular injury	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercalcaemia	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Proteinuria	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time prolonged	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood iron decreased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Bilirubin conjugated increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Megakaryocytes abnormal	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Aspartate aminotransferase increased	4 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal disorder	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Amylase increased	2 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 1 diabetes mellitus	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Azotaemia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus decreased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematuria	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count decreased	6 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pollakiuria	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thyroid stimulating hormone increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperlipasaemia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood urea increased	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancytopenia	2 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride decreased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoglycaemia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	International normalised ratio increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Alanine aminotransferase increased	2 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypokalaemia	4 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypernatraemia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophysitis	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphocyte count decreased	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphadenopathy	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoalbuminaemia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Anaemia	12 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood albumin decreased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulopathy	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile bone marrow aplasia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood glucose increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Tri-iodothyronine increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Eosinophil count increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis acute	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypomagnesaemia	2 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lipase increased	2 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic enzyme increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypocalcaemia	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood bilirubin increased	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Adrenal insufficiency	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Protein total decreased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Brain natriuretic peptide increased	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 2 diabetes mellitus	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic cytolysis	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Normocytic anaemia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphopenia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cells urine positive	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophosphataemia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count decreased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercholesterolaemia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thyroiditis	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulation time prolonged	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyponatraemia	2 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal failure	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Creatinine renal clearance decreased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium decreased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile neutropenia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyponatraemia	3 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophosphataemia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulopathy	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulation time prolonged	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile neutropenia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hydronephrosis	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoglycaemia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphocyte count decreased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypocalcaemia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophysitis	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count decreased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thyroid stimulating hormone increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal failure	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Tri-iodothyronine increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Procalcitonin increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Anaemia	5 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercholesterolaemia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cells urine positive	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Alanine aminotransferase increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Protein total decreased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypomagnesaemia	1 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium decreased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Eosinophil count increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic cytolysis	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile bone marrow aplasia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Brain natriuretic peptide increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 1 diabetes mellitus	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Normocytic anaemia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoalbuminaemia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Creatinine renal clearance decreased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	International normalised ratio increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypokalaemia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis acute	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood albumin decreased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time ratio increased	1 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphadenopathy	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood glucose increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Leukopenia	1 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood bilirubin increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypertransaminasaemia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphopenia	1 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Adrenal insufficiency	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Proteinuria	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 2 diabetes mellitus	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperkalaemia	2 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatine phosphokinase increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic enzyme increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cell count decreased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thrombocytopenia	1 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Liver function test increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Iron deficiency	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Aspartate aminotransferase increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood iron decreased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperlipasaemia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase decreased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatinine increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypernatraemia	1 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thyroiditis	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Azotaemia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatocellular injury	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Megakaryocytes abnormal	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count decreased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematocrit increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time prolonged	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	C-reactive protein increased	2 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thrombin increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haptoglobin increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperglycaemia	1 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypothyroidism	2 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood sodium decreased	1 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase increased	1 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood magnesium decreased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lipase increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Myocardial infarction	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Gamma-glutamyltransferase increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercalcaemia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen decreased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride decreased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count decreased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood alkaline phosphatase increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperthyroidism	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Vitamin B12 deficiency	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Folate deficiency	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Cushingoid	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutropenia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pollakiuria	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood urea increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematuria	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Amylase increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Bilirubin conjugated increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haemoglobin decreased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancytopenia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin T increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal disorder	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus decreased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperglycaemia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thrombin increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercalcaemia	2 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Myocardial infarction	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Creatinine renal clearance decreased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride decreased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thrombocytopenia	2 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	C-reactive protein increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count decreased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time prolonged	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus decreased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood alkaline phosphatase increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Vitamin B12 deficiency	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cell count decreased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count decreased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancytopenia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Megakaryocytes abnormal	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperkalaemia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Folate deficiency	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatocellular injury	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thyroiditis	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatinine increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypernatraemia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase decreased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutropenia	1 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatine phosphokinase increased	1 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pollakiuria	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal disorder	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperlipasaemia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematuria	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood iron decreased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Amylase increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium decreased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Bilirubin conjugated increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Aspartate aminotransferase increased	2 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Iron deficiency	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Liver function test increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulopathy	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic enzyme increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood magnesium decreased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphadenopathy	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lipase increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood sodium decreased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypothyroidism	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haemoglobin decreased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen decreased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematocrit increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin T increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Gamma-glutamyltransferase increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haptoglobin increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypomagnesaemia	1 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Eosinophil count increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Adrenal insufficiency	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercholesterolaemia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphocyte count decreased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperthyroidism	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic cytolysis	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile bone marrow aplasia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Normocytic anaemia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypokalaemia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	International normalised ratio increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time ratio increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood albumin decreased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Proteinuria	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypertransaminasaemia	1 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood glucose increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyponatraemia	1 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Tri-iodothyronine increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophosphataemia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile neutropenia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoglycaemia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 2 diabetes mellitus	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count decreased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cells urine positive	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Protein total decreased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophysitis	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Anaemia	7 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Procalcitonin increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Leukopenia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Brain natriuretic peptide increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypocalcaemia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphopenia	2 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulation time prolonged	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hydronephrosis	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Cushingoid	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis acute	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood bilirubin increased	1 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoalbuminaemia	1 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Azotaemia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood urea increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Alanine aminotransferase increased	2 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal failure	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thyroid stimulating hormone increased	1 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 1 diabetes mellitus	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haptoglobin increased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Cushingoid	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypomagnesaemia	3 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophosphataemia	4 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Tri-iodothyronine increased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyponatraemia	4 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal failure	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count increased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypertransaminasaemia	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Eosinophil count increased	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood bilirubin increased	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride increased	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood albumin decreased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphopenia	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphocyte count decreased	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin increased	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoalbuminaemia	5 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood urea increased	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	International normalised ratio increased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Adrenal insufficiency	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypokalaemia	2 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cells urine positive	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Normocytic anaemia	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Azotaemia	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypothyroidism	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Procalcitonin increased	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thyroiditis	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Anaemia	15 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	White blood cell count decreased	2 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic cytolysis	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancreatitis acute	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus increased	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Leukopenia	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thyroid stimulating hormone increased	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood chloride decreased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperthyroidism	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hydronephrosis	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercholesterolaemia	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypoglycaemia	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile neutropenia	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypophysitis	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Renal disorder	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Liver function test increased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutropenia	2 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 2 diabetes mellitus	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Proteinuria	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pollakiuria	2 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Gamma-glutamyltransferase increased	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood magnesium decreased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen decreased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Vitamin B12 deficiency	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lymphadenopathy	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Iron deficiency	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood phosphorus decreased	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperlipasaemia	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypercalcaemia	3 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperkalaemia	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood iron decreased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Thrombocytopenia	2 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood thrombin increased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Myocardial infarction	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Red blood cell count decreased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Creatinine renal clearance decreased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematocrit increased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hyperglycaemia	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	C-reactive protein increased	4 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypernatraemia	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time prolonged	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Brain natriuretic peptide increased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count increased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Aspartate aminotransferase increased	2 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count decreased	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatic enzyme increased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium increased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Lipase increased	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Amylase increased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Type 1 diabetes mellitus	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Folate deficiency	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Protein total decreased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Prothrombin time ratio increased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood calcium decreased	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood alkaline phosphatase increased	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Megakaryocytes abnormal	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase increased	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Alanine aminotransferase increased	3 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Bilirubin conjugated increased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Platelet count decreased	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haemoglobin decreased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulation time prolonged	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood sodium decreased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hypocalcaemia	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Neutrophil count increased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood glucose increased	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood fibrinogen increased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Hepatocellular injury	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Febrile bone marrow aplasia	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Pancytopenia	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatine phosphokinase increased	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood lactate dehydrogenase decreased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Blood creatinine increased	2 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Haematuria	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Coagulopathy	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Troponin T increased	0 Participants

Secondary

Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs

Number of participants with abnormal ECGs reported as TEAEs are reported.

Time frame: Day 1 thorugh 58.6 months (maximum observed duration)

Population: Safety analysis set included participants who received at least 1 dose of study drug and who were analyzed according to the actual treatment received and corresponding assigned cohort.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac failure	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial fibrillation	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac arrest	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Angina pectoris	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Heart rate irregular	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial flutter	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocardial ischaemia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Ventricular extrasystoles	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Supraventricular tachycardia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram QT prolonged	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Tachycardia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram RR interval prolonged	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrioventricular block second degree	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Acute myocardial infarction	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Sinus tachycardia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bundle branch block right	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocarditis	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Arrhythmia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myopericarditis	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bradycardia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrioventricular block second degree	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram QT prolonged	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac failure	2 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac arrest	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Supraventricular tachycardia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bradycardia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Tachycardia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Sinus tachycardia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocarditis	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocardial ischaemia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Heart rate irregular	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial flutter	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial fibrillation	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myopericarditis	1 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Acute myocardial infarction	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Ventricular extrasystoles	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Angina pectoris	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram RR interval prolonged	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Arrhythmia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bundle branch block right	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myopericarditis	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial fibrillation	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Acute myocardial infarction	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocardial ischaemia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram RR interval prolonged	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram QT prolonged	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac failure	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bundle branch block right	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Tachycardia	1 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac arrest	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocarditis	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Heart rate irregular	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bradycardia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Arrhythmia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrioventricular block second degree	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Sinus tachycardia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Supraventricular tachycardia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial flutter	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Ventricular extrasystoles	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Angina pectoris	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Acute myocardial infarction	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Tachycardia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Arrhythmia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Heart rate irregular	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bundle branch block right	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Angina pectoris	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Sinus tachycardia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Supraventricular tachycardia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial fibrillation	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram QT prolonged	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrioventricular block second degree	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial flutter	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram RR interval prolonged	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Ventricular extrasystoles	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myopericarditis	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac failure	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocarditis	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bradycardia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocardial ischaemia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac arrest	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram RR interval prolonged	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Sinus tachycardia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocarditis	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myopericarditis	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Arrhythmia	1 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac failure	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Tachycardia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Acute myocardial infarction	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrioventricular block second degree	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Angina pectoris	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bundle branch block right	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocardial ischaemia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram QT prolonged	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac arrest	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial fibrillation	1 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial flutter	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Heart rate irregular	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Supraventricular tachycardia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bradycardia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Ventricular extrasystoles	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial fibrillation	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Heart rate irregular	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram QT prolonged	1 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac arrest	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac failure	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Sinus tachycardia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Arrhythmia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Supraventricular tachycardia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Ventricular extrasystoles	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Acute myocardial infarction	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Angina pectoris	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Tachycardia	1 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial flutter	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrioventricular block second degree	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myopericarditis	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bradycardia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocarditis	1 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bundle branch block right	1 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocardial ischaemia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram RR interval prolonged	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Acute myocardial infarction	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Sinus tachycardia	2 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac failure	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram QT prolonged	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myopericarditis	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial fibrillation	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram RR interval prolonged	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrioventricular block second degree	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Heart rate irregular	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Angina pectoris	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac arrest	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Arrhythmia	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Tachycardia	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocarditis	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocardial ischaemia	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Ventricular extrasystoles	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Supraventricular tachycardia	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial flutter	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bradycardia	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bundle branch block right	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Tachycardia	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Sinus tachycardia	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Heart rate irregular	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram QT prolonged	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocarditis	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac arrest	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial flutter	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myopericarditis	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Arrhythmia	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Acute myocardial infarction	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Ventricular extrasystoles	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrioventricular block second degree	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bundle branch block right	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac failure	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Angina pectoris	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocardial ischaemia	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bradycardia	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial fibrillation	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram RR interval prolonged	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Supraventricular tachycardia	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrioventricular block second degree	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac arrest	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocarditis	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial fibrillation	2 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bradycardia	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac failure	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram RR interval prolonged	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Tachycardia	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Acute myocardial infarction	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Ventricular extrasystoles	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocardial ischaemia	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram QT prolonged	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial flutter	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myopericarditis	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bundle branch block right	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Sinus tachycardia	2 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Heart rate irregular	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Angina pectoris	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Arrhythmia	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Supraventricular tachycardia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bradycardia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial fibrillation	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myopericarditis	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Angina pectoris	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac failure	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Tachycardia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Ventricular extrasystoles	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Sinus tachycardia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial flutter	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Arrhythmia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrioventricular block second degree	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocarditis	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Supraventricular tachycardia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac arrest	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram QT prolonged	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bundle branch block right	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocardial ischaemia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Heart rate irregular	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram RR interval prolonged	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Acute myocardial infarction	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Tachycardia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Acute myocardial infarction	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram QT prolonged	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myopericarditis	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Sinus tachycardia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocarditis	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocardial ischaemia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac failure	1 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Angina pectoris	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram RR interval prolonged	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Ventricular extrasystoles	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrioventricular block second degree	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial flutter	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial fibrillation	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bundle branch block right	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Heart rate irregular	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bradycardia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Arrhythmia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac arrest	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Supraventricular tachycardia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Supraventricular tachycardia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocarditis	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac failure	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrioventricular block second degree	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocardial ischaemia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram QT prolonged	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Tachycardia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Arrhythmia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial flutter	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bundle branch block right	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Heart rate irregular	1 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myopericarditis	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Acute myocardial infarction	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram RR interval prolonged	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Angina pectoris	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial fibrillation	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Ventricular extrasystoles	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac arrest	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Sinus tachycardia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bradycardia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bundle branch block right	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac failure	1 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram QT prolonged	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac arrest	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Arrhythmia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Ventricular extrasystoles	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Acute myocardial infarction	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Angina pectoris	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial flutter	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrioventricular block second degree	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bradycardia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Heart rate irregular	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocardial ischaemia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocarditis	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Tachycardia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial fibrillation	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myopericarditis	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Sinus tachycardia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram RR interval prolonged	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Supraventricular tachycardia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocarditis	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Angina pectoris	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Sinus tachycardia	1 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myopericarditis	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Tachycardia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Arrhythmia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial flutter	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrioventricular block second degree	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bundle branch block right	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial fibrillation	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Supraventricular tachycardia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocardial ischaemia	1 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram QT prolonged	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Acute myocardial infarction	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Ventricular extrasystoles	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac arrest	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Heart rate irregular	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac failure	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bradycardia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram RR interval prolonged	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac failure	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocarditis	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Ventricular extrasystoles	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Heart rate irregular	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial flutter	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myopericarditis	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bradycardia	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram QT prolonged	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Arrhythmia	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Sinus tachycardia	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bundle branch block right	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrioventricular block second degree	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Supraventricular tachycardia	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial fibrillation	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac arrest	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Angina pectoris	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Tachycardia	2 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram RR interval prolonged	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Acute myocardial infarction	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocardial ischaemia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac failure	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Tachycardia	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Acute myocardial infarction	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bundle branch block right	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Heart rate irregular	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial flutter	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocardial ischaemia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram QT prolonged	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bradycardia	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac arrest	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocarditis	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Supraventricular tachycardia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrioventricular block second degree	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Arrhythmia	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myopericarditis	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram RR interval prolonged	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Sinus tachycardia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Ventricular extrasystoles	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Angina pectoris	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial fibrillation	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram RR interval prolonged	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocarditis	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Heart rate irregular	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Acute myocardial infarction	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Sinus tachycardia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac arrest	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bradycardia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram QT prolonged	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocardial ischaemia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Tachycardia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Ventricular extrasystoles	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial fibrillation	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac failure	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Angina pectoris	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Arrhythmia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myopericarditis	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bundle branch block right	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial flutter	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrioventricular block second degree	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Supraventricular tachycardia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocarditis	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram RR interval prolonged	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bundle branch block right	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocardial ischaemia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bradycardia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrioventricular block second degree	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Heart rate irregular	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial flutter	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Sinus tachycardia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Angina pectoris	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Tachycardia	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Acute myocardial infarction	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Ventricular extrasystoles	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial fibrillation	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myopericarditis	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Arrhythmia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac arrest	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Supraventricular tachycardia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram QT prolonged	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac failure	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Supraventricular tachycardia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrioventricular block second degree	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bradycardia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial fibrillation	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram QT prolonged	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Ventricular extrasystoles	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Sinus tachycardia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Angina pectoris	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Acute myocardial infarction	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial flutter	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram RR interval prolonged	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myopericarditis	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Heart rate irregular	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Arrhythmia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac failure	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Tachycardia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bundle branch block right	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac arrest	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocardial ischaemia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocarditis	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bundle branch block right	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Supraventricular tachycardia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Tachycardia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocardial ischaemia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocarditis	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrioventricular block second degree	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Sinus tachycardia	1 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bradycardia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myopericarditis	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Heart rate irregular	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Acute myocardial infarction	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram QT prolonged	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram RR interval prolonged	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Ventricular extrasystoles	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Arrhythmia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Angina pectoris	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac arrest	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial fibrillation	1 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac failure	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial flutter	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram QT prolonged	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Acute myocardial infarction	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial fibrillation	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Sinus tachycardia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Arrhythmia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Angina pectoris	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myopericarditis	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial flutter	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocarditis	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac arrest	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Heart rate irregular	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Supraventricular tachycardia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrioventricular block second degree	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram RR interval prolonged	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocardial ischaemia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bradycardia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac failure	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bundle branch block right	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Tachycardia	1 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Ventricular extrasystoles	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Heart rate irregular	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Sinus tachycardia	5 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bradycardia	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac failure	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Ventricular extrasystoles	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Cardiac arrest	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocarditis	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Acute myocardial infarction	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial flutter	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Bundle branch block right	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myopericarditis	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram RR interval prolonged	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Angina pectoris	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Arrhythmia	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrial fibrillation	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Electrocardiogram QT prolonged	2 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Atrioventricular block second degree	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Myocardial ischaemia	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Tachycardia	4 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs	Supraventricular tachycardia	0 Participants

Secondary

Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs

Number of participants with abnormal physical examination findings reported as TEAEs are reported. Any new or aggravated clinically relevant abnormal medical finding at a physical examination as compared with the pre-dose assessment was reported as an AE.

Time frame: Day 1 thorugh 58.6 months (maximum observed duration)

Population: Safety analysis set included participants who received at least 1 dose of study drug and who were analyzed according to the actual treatment received and corresponding assigned cohort.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Psoriasis	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Alopecia	1 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Eczema	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis allergic	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash	2 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Decubitus ulcer	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Ecchymosis	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dizziness	1 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Seborrhoeic dermatitis	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Peripheral ischaemia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Cardiac murmur	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Tremor	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin ulcer	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Myalgia	2 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Hypoxia	1 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Chronic obstructive pulmonary disease	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin induration	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pustular	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Depressed level of consciousness	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Vena cava thrombosis	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dehydration	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Erythema	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Nail disorder	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin irritation	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis acneiform	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Urticaria	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash maculo-papular	1 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Orthostatic hypotension	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin exfoliation	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin lesion	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin mass	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Transient ischaemic attack	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Weight decreased	2 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Headache	1 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dry skin	2 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Superior vena cava syndrome	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Lymphoedema	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash papular	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin discolouration	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis psoriasiform	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash macular	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Photosensitivity reaction	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Haematoma	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin hyperpigmentation	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Breath sounds	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pruritic	1 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin disorder	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash erythematous	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Petechiae	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Petechiae	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Weight decreased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis psoriasiform	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin lesion	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin disorder	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin hyperpigmentation	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash papular	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin mass	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dry skin	2 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pruritic	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Lymphoedema	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Seborrhoeic dermatitis	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Transient ischaemic attack	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Headache	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Haematoma	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash macular	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Photosensitivity reaction	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin discolouration	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Breath sounds	1 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash erythematous	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Chronic obstructive pulmonary disease	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Peripheral ischaemia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pustular	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Tremor	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin induration	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin exfoliation	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Nail disorder	1 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Orthostatic hypotension	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dizziness	2 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Superior vena cava syndrome	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Ecchymosis	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash	1 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Decubitus ulcer	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Eczema	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis allergic	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Psoriasis	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Alopecia	1 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Urticaria	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis acneiform	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dehydration	2 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin irritation	1 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Vena cava thrombosis	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Depressed level of consciousness	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Hypoxia	2 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Cardiac murmur	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Myalgia	1 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Erythema	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash maculo-papular	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin ulcer	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Weight decreased	3 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Urticaria	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin exfoliation	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Cardiac murmur	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash macular	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Hypoxia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Ecchymosis	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Nail disorder	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin induration	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dehydration	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin discolouration	1 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Vena cava thrombosis	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Decubitus ulcer	2 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin irritation	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Peripheral ischaemia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Depressed level of consciousness	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Chronic obstructive pulmonary disease	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Myalgia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis allergic	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Eczema	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Alopecia	1 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dry skin	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Tremor	1 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Superior vena cava syndrome	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Orthostatic hypotension	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dizziness	4 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis acneiform	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin ulcer	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pustular	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Seborrhoeic dermatitis	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Erythema	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis psoriasiform	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Lymphoedema	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash erythematous	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin hyperpigmentation	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Transient ischaemic attack	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Headache	5 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Haematoma	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Photosensitivity reaction	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Psoriasis	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Petechiae	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Breath sounds	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin lesion	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash	1 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin disorder	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin mass	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash papular	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pruritic	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash maculo-papular	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Lymphoedema	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin disorder	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Weight decreased	1 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash erythematous	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash maculo-papular	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Transient ischaemic attack	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Photosensitivity reaction	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Petechiae	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin mass	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash	3 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Erythema	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis psoriasiform	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin induration	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Seborrhoeic dermatitis	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pustular	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash papular	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pruritic	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin lesion	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Breath sounds	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Haematoma	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin hyperpigmentation	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Psoriasis	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Orthostatic hypotension	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Eczema	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin exfoliation	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis allergic	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dry skin	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Peripheral ischaemia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Headache	3 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin discolouration	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis acneiform	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Ecchymosis	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash macular	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Alopecia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Urticaria	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Depressed level of consciousness	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dehydration	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Chronic obstructive pulmonary disease	2 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Nail disorder	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Vena cava thrombosis	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Tremor	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin ulcer	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Hypoxia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Cardiac murmur	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin irritation	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dizziness	2 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Superior vena cava syndrome	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Myalgia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Decubitus ulcer	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Hypoxia	2 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Peripheral ischaemia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Orthostatic hypotension	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Cardiac murmur	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Eczema	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Urticaria	1 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin irritation	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Superior vena cava syndrome	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis allergic	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Chronic obstructive pulmonary disease	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash macular	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Myalgia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dizziness	2 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Decubitus ulcer	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Ecchymosis	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Alopecia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis acneiform	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin ulcer	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Nail disorder	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dehydration	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Seborrhoeic dermatitis	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Vena cava thrombosis	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin disorder	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin exfoliation	1 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Headache	1 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Depressed level of consciousness	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dry skin	1 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Weight decreased	4 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin mass	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash maculo-papular	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin hyperpigmentation	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pruritic	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash papular	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis psoriasiform	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Erythema	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin induration	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Psoriasis	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Haematoma	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Photosensitivity reaction	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash erythematous	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin discolouration	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Petechiae	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Breath sounds	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin lesion	1 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Lymphoedema	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pustular	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Tremor	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Transient ischaemic attack	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Photosensitivity reaction	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash maculo-papular	1 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Lymphoedema	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin induration	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Weight decreased	2 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pustular	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Tremor	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Haematoma	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash papular	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Erythema	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin hyperpigmentation	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pruritic	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Transient ischaemic attack	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dry skin	2 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash	2 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin mass	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin lesion	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Breath sounds	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Petechiae	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Psoriasis	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Superior vena cava syndrome	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash erythematous	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Urticaria	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Peripheral ischaemia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Nail disorder	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Ecchymosis	1 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Headache	1 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis allergic	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis psoriasiform	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis acneiform	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Alopecia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Depressed level of consciousness	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dehydration	1 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Cardiac murmur	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Hypoxia	1 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Myalgia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin ulcer	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Chronic obstructive pulmonary disease	1 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Seborrhoeic dermatitis	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash macular	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Vena cava thrombosis	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin discolouration	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Decubitus ulcer	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Eczema	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin irritation	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Orthostatic hypotension	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dizziness	3 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin exfoliation	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin disorder	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin disorder	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis acneiform	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash macular	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Alopecia	3 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Vena cava thrombosis	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Decubitus ulcer	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash erythematous	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Eczema	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis allergic	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Chronic obstructive pulmonary disease	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis psoriasiform	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin exfoliation	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dehydration	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Urticaria	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Peripheral ischaemia	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Depressed level of consciousness	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Cardiac murmur	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Orthostatic hypotension	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dizziness	2 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Ecchymosis	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Headache	6 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin irritation	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin ulcer	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin discolouration	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin induration	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pustular	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Haematoma	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Weight decreased	2 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Photosensitivity reaction	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin lesion	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash	5 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Psoriasis	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Hypoxia	2 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Transient ischaemic attack	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Breath sounds	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Erythema	2 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Myalgia	4 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Nail disorder	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash papular	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin hyperpigmentation	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin mass	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Superior vena cava syndrome	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dry skin	4 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash maculo-papular	3 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Lymphoedema	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Petechiae	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pruritic	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Tremor	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Seborrhoeic dermatitis	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Chronic obstructive pulmonary disease	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Tremor	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash maculo-papular	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin lesion	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Breath sounds	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pustular	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Lymphoedema	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Myalgia	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Petechiae	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin hyperpigmentation	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Haematoma	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin induration	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Psoriasis	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Transient ischaemic attack	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Weight decreased	3 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Erythema	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Nail disorder	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Hypoxia	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pruritic	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dry skin	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Photosensitivity reaction	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash papular	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Superior vena cava syndrome	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin ulcer	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin mass	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Vena cava thrombosis	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Cardiac murmur	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dehydration	4 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Urticaria	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Depressed level of consciousness	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin discolouration	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis acneiform	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Decubitus ulcer	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis allergic	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash erythematous	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Eczema	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis psoriasiform	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash	3 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin irritation	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Headache	5 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Ecchymosis	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dizziness	5 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Alopecia	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Orthostatic hypotension	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin disorder	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Peripheral ischaemia	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Seborrhoeic dermatitis	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash macular	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin exfoliation	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Headache	7 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Vena cava thrombosis	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Peripheral ischaemia	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin lesion	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Seborrhoeic dermatitis	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Urticaria	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Ecchymosis	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash macular	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Depressed level of consciousness	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin ulcer	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis allergic	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Orthostatic hypotension	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis acneiform	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Cardiac murmur	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Eczema	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Decubitus ulcer	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin disorder	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dizziness	9 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin induration	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis psoriasiform	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin irritation	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin exfoliation	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Alopecia	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash erythematous	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Erythema	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Weight decreased	10 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dry skin	7 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dehydration	4 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Hypoxia	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Myalgia	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash maculo-papular	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Chronic obstructive pulmonary disease	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Tremor	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pruritic	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Haematoma	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Photosensitivity reaction	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin hyperpigmentation	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Psoriasis	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin discolouration	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Breath sounds	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash papular	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pustular	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Superior vena cava syndrome	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Lymphoedema	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Nail disorder	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin mass	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Petechiae	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Transient ischaemic attack	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Transient ischaemic attack	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Urticaria	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin discolouration	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Headache	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Erythema	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Haematoma	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pruritic	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash maculo-papular	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin ulcer	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Tremor	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Myalgia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash papular	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Superior vena cava syndrome	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Breath sounds	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Psoriasis	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Chronic obstructive pulmonary disease	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin hyperpigmentation	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dehydration	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Lymphoedema	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dry skin	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pustular	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Nail disorder	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Orthostatic hypotension	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dizziness	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Weight decreased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash	1 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Alopecia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Hypoxia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin lesion	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Eczema	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin disorder	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Photosensitivity reaction	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash erythematous	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin exfoliation	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin irritation	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Decubitus ulcer	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Vena cava thrombosis	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash macular	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Seborrhoeic dermatitis	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin induration	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Cardiac murmur	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Depressed level of consciousness	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis acneiform	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis allergic	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis psoriasiform	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Ecchymosis	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Peripheral ischaemia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin mass	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Petechiae	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash erythematous	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin exfoliation	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis acneiform	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Photosensitivity reaction	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis psoriasiform	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Ecchymosis	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Vena cava thrombosis	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Orthostatic hypotension	1 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Decubitus ulcer	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Peripheral ischaemia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin induration	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis allergic	1 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin irritation	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Weight decreased	2 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Depressed level of consciousness	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Cardiac murmur	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Alopecia	1 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Petechiae	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin lesion	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin disorder	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Hypoxia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dizziness	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash macular	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Psoriasis	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Seborrhoeic dermatitis	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash maculo-papular	2 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Haematoma	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin hyperpigmentation	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Headache	3 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Transient ischaemic attack	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin mass	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin discolouration	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Urticaria	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Nail disorder	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dry skin	1 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Lymphoedema	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dehydration	2 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Eczema	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Breath sounds	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Superior vena cava syndrome	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Myalgia	1 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pruritic	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Erythema	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash papular	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Tremor	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pustular	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin ulcer	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Chronic obstructive pulmonary disease	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Eczema	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin irritation	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Psoriasis	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dehydration	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Headache	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Superior vena cava syndrome	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Urticaria	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin discolouration	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Chronic obstructive pulmonary disease	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash papular	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin ulcer	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Tremor	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Nail disorder	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash maculo-papular	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pruritic	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Haematoma	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin induration	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pustular	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Transient ischaemic attack	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Decubitus ulcer	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash macular	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Vena cava thrombosis	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Breath sounds	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Erythema	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin mass	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Ecchymosis	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Alopecia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Hypoxia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis acneiform	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin exfoliation	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Peripheral ischaemia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin hyperpigmentation	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Orthostatic hypotension	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Myalgia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin disorder	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis allergic	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Depressed level of consciousness	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dry skin	1 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Photosensitivity reaction	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin lesion	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis psoriasiform	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Seborrhoeic dermatitis	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dizziness	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Weight decreased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Cardiac murmur	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Petechiae	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash erythematous	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Lymphoedema	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Decubitus ulcer	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin ulcer	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin induration	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Weight decreased	1 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Peripheral ischaemia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Orthostatic hypotension	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin lesion	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash papular	1 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Alopecia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Ecchymosis	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Erythema	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin mass	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pruritic	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Myalgia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Cardiac murmur	1 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis psoriasiform	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Seborrhoeic dermatitis	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Vena cava thrombosis	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash	1 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash erythematous	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin disorder	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dry skin	2 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Photosensitivity reaction	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Breath sounds	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Lymphoedema	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Hypoxia	1 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Petechiae	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash macular	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Depressed level of consciousness	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis allergic	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin hyperpigmentation	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis acneiform	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin irritation	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Nail disorder	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Urticaria	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin exfoliation	1 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Psoriasis	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dehydration	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Superior vena cava syndrome	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Eczema	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Chronic obstructive pulmonary disease	1 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pustular	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Haematoma	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Tremor	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash maculo-papular	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Headache	1 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dizziness	4 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Transient ischaemic attack	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin discolouration	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Vena cava thrombosis	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Psoriasis	1 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin induration	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pustular	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Chronic obstructive pulmonary disease	1 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Seborrhoeic dermatitis	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Tremor	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Nail disorder	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin exfoliation	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin discolouration	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin irritation	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Urticaria	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Headache	1 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Superior vena cava syndrome	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Eczema	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dizziness	3 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin lesion	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash maculo-papular	1 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Transient ischaemic attack	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis acneiform	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Alopecia	4 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Petechiae	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Depressed level of consciousness	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Orthostatic hypotension	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Peripheral ischaemia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin hyperpigmentation	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Haematoma	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dehydration	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Decubitus ulcer	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash erythematous	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Myalgia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Lymphoedema	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pruritic	1 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Erythema	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Ecchymosis	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash macular	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash papular	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin disorder	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Weight decreased	5 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis psoriasiform	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Breath sounds	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin mass	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Photosensitivity reaction	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis allergic	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash	3 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dry skin	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Hypoxia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Cardiac murmur	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin ulcer	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash papular	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Alopecia	7 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin discolouration	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Cardiac murmur	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Orthostatic hypotension	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin hyperpigmentation	2 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Tremor	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dehydration	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Weight decreased	2 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Haematoma	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Breath sounds	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Lymphoedema	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Peripheral ischaemia	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Petechiae	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pruritic	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis acneiform	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin disorder	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis psoriasiform	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash macular	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Ecchymosis	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Seborrhoeic dermatitis	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Erythema	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin ulcer	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Myalgia	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Superior vena cava syndrome	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Depressed level of consciousness	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash erythematous	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin induration	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dry skin	2 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis allergic	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin exfoliation	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Hypoxia	2 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin irritation	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin mass	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash maculo-papular	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin lesion	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Decubitus ulcer	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pustular	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Photosensitivity reaction	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dizziness	3 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Psoriasis	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Eczema	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Nail disorder	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Chronic obstructive pulmonary disease	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Transient ischaemic attack	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Headache	4 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Vena cava thrombosis	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Urticaria	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin disorder	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Decubitus ulcer	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Psoriasis	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin exfoliation	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin irritation	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Urticaria	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Vena cava thrombosis	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Eczema	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Chronic obstructive pulmonary disease	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Transient ischaemic attack	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pustular	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Seborrhoeic dermatitis	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin mass	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin ulcer	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis allergic	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis psoriasiform	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin induration	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Hypoxia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Nail disorder	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dizziness	4 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Headache	3 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Petechiae	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Photosensitivity reaction	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Ecchymosis	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pruritic	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Cardiac murmur	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Superior vena cava syndrome	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Tremor	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Weight decreased	5 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Lymphoedema	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Myalgia	2 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash erythematous	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Alopecia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin discolouration	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin lesion	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Breath sounds	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Peripheral ischaemia	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Haematoma	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis acneiform	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash maculo-papular	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin hyperpigmentation	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dehydration	2 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Orthostatic hypotension	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dry skin	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash	2 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Erythema	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Depressed level of consciousness	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash macular	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash papular	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin hyperpigmentation	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin lesion	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Erythema	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin discolouration	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Lymphoedema	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Cardiac murmur	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Orthostatic hypotension	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Tremor	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dry skin	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Depressed level of consciousness	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Psoriasis	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Seborrhoeic dermatitis	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Peripheral ischaemia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Haematoma	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pruritic	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Decubitus ulcer	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash maculo-papular	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash papular	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Breath sounds	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash	2 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis acneiform	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dehydration	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Myalgia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash erythematous	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Vena cava thrombosis	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Chronic obstructive pulmonary disease	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Nail disorder	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin disorder	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Urticaria	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin mass	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Photosensitivity reaction	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis psoriasiform	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Weight decreased	4 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis allergic	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin exfoliation	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin induration	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Hypoxia	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin irritation	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Transient ischaemic attack	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash macular	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Eczema	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Superior vena cava syndrome	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin ulcer	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Petechiae	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Ecchymosis	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Headache	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dizziness	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pustular	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Alopecia	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Alopecia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Petechiae	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Transient ischaemic attack	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Vena cava thrombosis	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dizziness	2 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash macular	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pustular	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Seborrhoeic dermatitis	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Urticaria	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Ecchymosis	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Photosensitivity reaction	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Eczema	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin irritation	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Weight decreased	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis allergic	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Nail disorder	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Superior vena cava syndrome	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin exfoliation	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Headache	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin induration	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin ulcer	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Hypoxia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Haematoma	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash erythematous	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Psoriasis	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Orthostatic hypotension	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Decubitus ulcer	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin lesion	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin discolouration	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin disorder	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pruritic	2 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Erythema	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Peripheral ischaemia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash papular	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Tremor	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Chronic obstructive pulmonary disease	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin mass	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Breath sounds	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash maculo-papular	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dehydration	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Cardiac murmur	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Depressed level of consciousness	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dry skin	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis acneiform	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash	5 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis psoriasiform	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Lymphoedema	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Myalgia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin hyperpigmentation	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash papular	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Tremor	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis acneiform	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pustular	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin mass	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dry skin	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Chronic obstructive pulmonary disease	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin lesion	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Seborrhoeic dermatitis	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Peripheral ischaemia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dizziness	2 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis psoriasiform	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin hyperpigmentation	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Cardiac murmur	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dehydration	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Psoriasis	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin disorder	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Myalgia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Decubitus ulcer	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash	5 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Orthostatic hypotension	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Eczema	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Lymphoedema	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash maculo-papular	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pruritic	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Haematoma	2 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Breath sounds	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Depressed level of consciousness	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Erythema	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Alopecia	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Photosensitivity reaction	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis allergic	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Hypoxia	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash macular	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin induration	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Superior vena cava syndrome	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Ecchymosis	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Vena cava thrombosis	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Urticaria	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Transient ischaemic attack	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin discolouration	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Nail disorder	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Headache	2 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash erythematous	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Petechiae	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin irritation	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Weight decreased	4 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin exfoliation	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin ulcer	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Nail disorder	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin induration	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash	2 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Transient ischaemic attack	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Headache	3 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Ecchymosis	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash erythematous	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Superior vena cava syndrome	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Petechiae	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin irritation	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis allergic	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Photosensitivity reaction	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Weight decreased	1 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin ulcer	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Orthostatic hypotension	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Urticaria	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin discolouration	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash macular	1 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Vena cava thrombosis	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Depressed level of consciousness	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Alopecia	2 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin exfoliation	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis acneiform	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Cardiac murmur	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dehydration	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Myalgia	1 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Breath sounds	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash maculo-papular	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin mass	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Peripheral ischaemia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Seborrhoeic dermatitis	1 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis psoriasiform	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dizziness	2 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Chronic obstructive pulmonary disease	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pustular	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash papular	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Tremor	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Erythema	1 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pruritic	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Lymphoedema	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Haematoma	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Eczema	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Psoriasis	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin disorder	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Hypoxia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin lesion	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Decubitus ulcer	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin hyperpigmentation	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dry skin	1 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin disorder	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dehydration	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash maculo-papular	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dry skin	2 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Lymphoedema	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis acneiform	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Depressed level of consciousness	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin lesion	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin exfoliation	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Cardiac murmur	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis psoriasiform	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Haematoma	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dizziness	3 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Erythema	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Tremor	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Myalgia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Alopecia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin discolouration	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Chronic obstructive pulmonary disease	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Breath sounds	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin hyperpigmentation	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pruritic	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pustular	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Decubitus ulcer	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Psoriasis	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin mass	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash papular	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Headache	2 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Ecchymosis	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Orthostatic hypotension	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Transient ischaemic attack	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Superior vena cava syndrome	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis allergic	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Hypoxia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Petechiae	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Photosensitivity reaction	1 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Weight decreased	1 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Urticaria	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Nail disorder	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin ulcer	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin induration	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash	2 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash macular	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Vena cava thrombosis	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash erythematous	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Seborrhoeic dermatitis	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Peripheral ischaemia	1 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin irritation	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Eczema	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash macular	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Haematoma	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Transient ischaemic attack	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis acneiform	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin ulcer	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis allergic	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Peripheral ischaemia	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash erythematous	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Ecchymosis	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin irritation	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin induration	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Petechiae	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Hypoxia	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Orthostatic hypotension	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Vena cava thrombosis	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Photosensitivity reaction	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash	2 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Urticaria	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Weight decreased	9 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Superior vena cava syndrome	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Eczema	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dizziness	3 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash papular	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin mass	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Alopecia	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Tremor	2 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Erythema	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Myalgia	3 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin hyperpigmentation	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Lymphoedema	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Decubitus ulcer	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin exfoliation	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Breath sounds	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Depressed level of consciousness	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Nail disorder	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pruritic	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin disorder	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dry skin	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dehydration	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Seborrhoeic dermatitis	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin lesion	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Dermatitis psoriasiform	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Cardiac murmur	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Psoriasis	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash maculo-papular	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Headache	9 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Chronic obstructive pulmonary disease	2 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Skin discolouration	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs	Rash pustular	0 Participants

Secondary

Number of Participants With Abnormal Vital Signs Reported as TEAEs

Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal finding in the vital sign parameters (blood pressure, pulse rate, temperature, and respiration rate).

Time frame: Day 1 thorugh 58.6 months (maximum observed duration)

Population: Safety analysis set included participants who received at least 1 dose of study drug and who were analyzed according to the actual treatment received and corresponding assigned cohort.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure systolic increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea exertional	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertensive crisis	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure increased	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea	6 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Heart rate irregular	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Tachycardia	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertension	2 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypotension	0 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Bradycardia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertension	1 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure systolic increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Heart rate irregular	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Bradycardia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertensive crisis	1 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea exertional	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure increased	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypotension	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Tachycardia	0 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea	2 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypotension	3 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertension	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertensive crisis	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Heart rate irregular	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea exertional	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure systolic increased	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Bradycardia	0 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Tachycardia	1 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea	5 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertensive crisis	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertension	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure systolic increased	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea exertional	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Tachycardia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Bradycardia	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypotension	0 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea	4 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Heart rate irregular	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypotension	1 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea exertional	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure systolic increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure increased	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertension	1 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Heart rate irregular	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea	6 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Tachycardia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Bradycardia	0 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertensive crisis	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypotension	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Bradycardia	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure systolic increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertensive crisis	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea	5 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea exertional	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Heart rate irregular	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertension	1 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure increased	0 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Tachycardia	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea	7 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Tachycardia	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Bradycardia	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertensive crisis	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure systolic increased	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Heart rate irregular	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea exertional	0 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertension	1 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypotension	3 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure increased	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea	6 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea exertional	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Tachycardia	1 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Heart rate irregular	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Bradycardia	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypotension	4 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertension	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertensive crisis	0 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure systolic increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Tachycardia	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea	9 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Heart rate irregular	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure systolic increased	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertension	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Bradycardia	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea exertional	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure increased	1 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertensive crisis	0 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypotension	3 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure systolic increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure increased	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea exertional	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Tachycardia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Bradycardia	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertension	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypotension	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertensive crisis	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Heart rate irregular	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure systolic increased	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Bradycardia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Heart rate irregular	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertension	1 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypotension	2 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Tachycardia	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertensive crisis	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea	6 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea exertional	0 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure increased	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea exertional	1 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure systolic increased	1 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea	1 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Bradycardia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypotension	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Heart rate irregular	1 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertensive crisis	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertension	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Tachycardia	0 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea exertional	1 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertension	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea	2 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypotension	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure systolic increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Heart rate irregular	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure increased	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Bradycardia	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertensive crisis	0 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Tachycardia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Heart rate irregular	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Tachycardia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertension	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Bradycardia	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertensive crisis	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea	2 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypotension	2 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure systolic increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure increased	0 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea exertional	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea	6 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Tachycardia	2 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypotension	2 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure systolic increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertensive crisis	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Bradycardia	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure increased	0 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertension	1 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea exertional	2 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Heart rate irregular	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Heart rate irregular	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure systolic increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Tachycardia	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea	3 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure increased	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypotension	4 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea exertional	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Bradycardia	1 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertensive crisis	0 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertension	5 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea	3 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertension	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea exertional	2 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Heart rate irregular	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure systolic increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure increased	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Bradycardia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypotension	1 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Tachycardia	0 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertensive crisis	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea exertional	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypotension	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Heart rate irregular	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertensive crisis	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertension	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Bradycardia	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea	3 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Tachycardia	1 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure increased	0 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure systolic increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure systolic increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypotension	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea exertional	1 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure increased	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertensive crisis	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertension	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Bradycardia	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea	2 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Heart rate irregular	0 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Tachycardia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Heart rate irregular	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Bradycardia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertension	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertensive crisis	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea	5 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Tachycardia	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea exertional	1 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure systolic increased	0 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypotension	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea	2 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypotension	1 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea exertional	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertension	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertensive crisis	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Bradycardia	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Tachycardia	1 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure systolic increased	0 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Heart rate irregular	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Tachycardia	4 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea exertional	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertension	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure systolic increased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypertensive crisis	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Bradycardia	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Dyspnoea	6 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Heart rate irregular	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Blood pressure increased	0 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Abnormal Vital Signs Reported as TEAEs	Hypotension	3 Participants

Secondary

Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

Time frame: Day 1 thorugh 58.6 months (maximum observed duration)

Population: Safety analysis set included participants who received at least 1 dose of study drug and who were analyzed according to the actual treatment received and corresponding assigned cohort.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TEAEs	20 Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TESAEs	10 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TESAEs	7 Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TEAEs	19 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TESAEs	8 Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TEAEs	20 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TEAEs	21 Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TESAEs	7 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TESAEs	12 Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TEAEs	23 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TESAEs	8 Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TEAEs	20 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TESAEs	11 Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TEAEs	31 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TESAEs	11 Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TEAEs	35 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TESAEs	17 Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TEAEs	56 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TESAEs	0 Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TEAEs	1 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TEAEs	21 Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TESAEs	7 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TESAEs	1 Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TEAEs	5 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TESAEs	6 Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TEAEs	22 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TEAEs	23 Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TESAEs	10 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TEAEs	20 Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TESAEs	10 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TESAEs	7 Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TEAEs	21 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TESAEs	7 Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TEAEs	15 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TESAEs	7 Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TEAEs	17 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TESAEs	13 Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TEAEs	24 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TESAEs	12 Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TEAEs	32 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TEAEs	16 Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TESAEs	1 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TESAEs	17 Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)	Any TEAEs	38 Participants

Secondary

Overall Survival (OS)

The OS is defined as the time from the first dose of any study drug until death due to any cause regardless of whether the participant withdraws from study treatment or receives subsequent cancer therapy. The overall survival was analyzed using the Kaplan-Meier method.

Time frame: Every 3 months after safety follow-up visit (90 days after study drug discontinuation) until planned database lock for a module (either 12 months after last participant has started treatment or when 75% of participants died) (approximately up to 2 years)

Population: Intention to treat (ITT) analysis population included all enrolled participants who received at least 1 dose of the study drug and were analyzed according to their assigned cohort and planned treatment.

Arm	Measure	Value (MEDIAN)
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Overall Survival (OS)	9.63 Months
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Overall Survival (OS)	5.75 Months
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Overall Survival (OS)	7.16 Months
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Overall Survival (OS)	15.51 Months
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Overall Survival (OS)	6.01 Months
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Overall Survival (OS)	11.20 Months
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Overall Survival (OS)	15.80 Months
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Overall Survival (OS)	10.22 Months
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Overall Survival (OS)	11.37 Months
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Overall Survival (OS)	NA Months
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Overall Survival (OS)	10.97 Months
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Overall Survival (OS)	7.06 Months
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Overall Survival (OS)	12.78 Months
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Overall Survival (OS)	9.53 Months
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Overall Survival (OS)	10.61 Months
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Overall Survival (OS)	14.19 Months
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Overall Survival (OS)	14.23 Months
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Overall Survival (OS)	7.95 Months
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Overall Survival (OS)	12.91 Months
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Overall Survival (OS)	5.95 Months
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Overall Survival (OS)	7.03 Months
Module 11 Cohort C.11.240: AZD6738 240 mg	Overall Survival (OS)	6.60 Months

Secondary

Percentage of Participants With Disease Control (DC) Per RECIST v1.1

Module (M) 1, 4, 5, 6, 7, 8, 9, 11: DCR at 12 and 24 weeks is defined as percentage of participants who have best overall response (BoR) of CR or PR in first 13/25 weeks, respectively, post start of any study drug or with duration of SD for at least 11/23 weeks, respectively, after start of any study drug. M2, M3, M10: DCR at 12 and 24 weeks is defined as percentage of participants who have BoR of CR or PR within first 100 days (M2, M3, M10) or 184 days (M2, M3, M10) after start of any study drug, or have SD lasting at least 86 days (M2)/82 days (M3, M10), respectively, or 170 days (M2)/166 days (M3, M10), respectively, post start of any study drug. CR is defined as disappearance of all TL and NTLs, and any pathological lymph node (whether target or nontarget) must have reduction in short axis to \<10 mm. PR is defined as at least 30% decrease in sum of diameters of TLs, taking as reference baseline sum diameters, as long as criteria for PD are not met.

Time frame: At 12 and 24 weeks after the start of study drug

Population: Evaluable for response population included all dosed participants who had measurable disease at baseline and who were analyzed according to their assigned cohort and planned treatment.

Arm	Measure	Group	Value (NUMBER)
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 24 weeks	19.0 Percentage of Participants
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 weeks	38.1 Percentage of Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 24 weeks	9.5 Percentage of Participants
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 weeks	9.5 Percentage of Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 weeks	45.5 Percentage of Participants
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 24 weeks	13.6 Percentage of Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 24 weeks	26.1 Percentage of Participants
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 weeks	52.2 Percentage of Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 24 weeks	0 Percentage of Participants
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 weeks	13.0 Percentage of Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 weeks	40.9 Percentage of Participants
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 24 weeks	27.3 Percentage of Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 weeks	67.7 Percentage of Participants
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 24 weeks	58.1 Percentage of Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 weeks	54.1 Percentage of Participants
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 24 weeks	27.0 Percentage of Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 weeks	58.6 Percentage of Participants
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 24 weeks	34.5 Percentage of Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 weeks	NA Percentage of Participants
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 24 weeks	NA Percentage of Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 24 weeks	8.7 Percentage of Participants
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 weeks	34.8 Percentage of Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 weeks	22.2 Percentage of Participants
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 24 weeks	11.1 Percentage of Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 24 weeks	24.0 Percentage of Participants
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 weeks	56.0 Percentage of Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 24 weeks	34.8 Percentage of Participants
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 weeks	56.5 Percentage of Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 24 weeks	60.0 Percentage of Participants
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 weeks	70.0 Percentage of Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 weeks	63.6 Percentage of Participants
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 24 weeks	45.5 Percentage of Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 weeks	60.0 Percentage of Participants
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 24 weeks	40.0 Percentage of Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 24 weeks	16.7 Percentage of Participants
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 weeks	22.2 Percentage of Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 weeks	58.3 Percentage of Participants
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 24 weeks	33.3 Percentage of Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 24 weeks	17.6 Percentage of Participants
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 weeks	32.4 Percentage of Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 weeks	41.2 Percentage of Participants
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 24 weeks	23.5 Percentage of Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 12 weeks	60.5 Percentage of Participants
Module 11 Cohort C.11.240: AZD6738 240 mg	Percentage of Participants With Disease Control (DC) Per RECIST v1.1	At 24 weeks	26.3 Percentage of Participants

Secondary

Progression-Free Survival (PFS) Per RECIST v1.1

The PFS is defined as time from first dose of any study drug until date of objective disease progression (PD) per RECIST v1.1 or death by any cause, regardless of whether the participant withdraws from study therapy or receives another anti-cancer therapy prior to progression. The PD is defined as a \>= 20% increase in the sum of diameters of TLs and an absolute increase of \>= 5mm, taking as reference the smallest sum of diameters since treatment started including the baseline sum of diameters, or unequivocal progression of existing NTL. The PFS was analyzed using the Kaplan-Meier method

Population: The ITT analysis population included all enrolled participants who received at least 1 dose of the study drug and were analyzed according to their assigned cohort and planned treatment.

Arm	Measure	Value (MEDIAN)
Module 1 Cohort A.1.HRR: Durvalumab 1500 mg + Olaparib 300 mg	Progression-Free Survival (PFS) Per RECIST v1.1	2.79 Months
Module 1 Cohort A.1.LKB: Durvalumab 1500 mg + Olaparib 300 mg	Progression-Free Survival (PFS) Per RECIST v1.1	1.41 Months
Module 1 Cohort B.1.PRI: Durvalumab 1500 mg + Olaparib 300 mg	Progression-Free Survival (PFS) Per RECIST v1.1	3.38 Months
Module 1 Cohort B.1.ACQ: Durvalumab 1500 mg + Olaparib 300 mg	Progression-Free Survival (PFS) Per RECIST v1.1	4.17 Months
Module 2 Cohort B.2.PRI: Durvalumab 1500 mg + Danvatirsen 200 mg	Progression-Free Survival (PFS) Per RECIST v1.1	1.68 Months
Module 2 Cohort B.2.ACQ: Durvalumab 1500 mg + Danvatirsen 200 mg	Progression-Free Survival (PFS) Per RECIST v1.1	3.09 Months
Module 3 Cohort A.3.ATM: Durvalumab 1500 mg + AZD6738 240 mg	Progression-Free Survival (PFS) Per RECIST v1.1	7.43 Months
Module 3 Cohort B.3.PRI: Durvalumab 1500 mg + AZD6738 240 mg	Progression-Free Survival (PFS) Per RECIST v1.1	2.96 Months
Module 3 Cohort B.3.ACQ: Durvalumab 1500 mg + AZD6738 240 mg	Progression-Free Survival (PFS) Per RECIST v1.1	4.21 Months
Module 4 Cohort A.4.RIC: Durvalumab 1500 mg + Vistusertib 125 mg	Progression-Free Survival (PFS) Per RECIST v1.1	NA Months
Module 5 Cohort A.5.73H: Durvalumab 1500 mg + Oleclumab 3000 mg	Progression-Free Survival (PFS) Per RECIST v1.1	1.61 Months
Module 5 Cohort B.5.PRI: Durvalumab 1500 mg + Oleclumab 3000 mg	Progression-Free Survival (PFS) Per RECIST v1.1	1.41 Months
Module 5 Cohort B.5.ACQ: Durvalumab 1500 mg + Oleclumab 3000 mg	Progression-Free Survival (PFS) Per RECIST v1.1	2.69 Months
Module 6 Cohort A.6.HER2e: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Progression-Free Survival (PFS) Per RECIST v1.1	2.83 Months
Module 6 Cohort A.6.HER2m: Durvalumab 1120 mg + Trastuzumab Deruxtecan 5.4mg/kg	Progression-Free Survival (PFS) Per RECIST v1.1	5.52 Months
Module 7 Cohort B.7.ACQ: Durvalumab 1500 mg + Cediranib 20 mg	Progression-Free Survival (PFS) Per RECIST v1.1	4.17 Months
Module 8 Cohort A.8.ATM: Ceralasertib 240 mg	Progression-Free Survival (PFS) Per RECIST v1.1	3.42 Months
Module 9 Cohort B.9.PRI: Durvalumab 1500 mg + Ceralasertib 240 mg	Progression-Free Survival (PFS) Per RECIST v1.1	1.48 Months
Module 9 Cohort B.9.ACQ: Durvalumab 1500 mg + Ceralasertib 240 mg	Progression-Free Survival (PFS) Per RECIST v1.1	3.68 Months
Module 10 Cohort C.10.160: Durvalumab 1500 mg + Ceralasertib 160 mg	Progression-Free Survival (PFS) Per RECIST v1.1	1.68 Months
Module 10 Cohort C.10.240: Durvalumab 1500 mg + Ceralasertib 240 mg	Progression-Free Survival (PFS) Per RECIST v1.1	2.00 Months
Module 11 Cohort C.11.240: AZD6738 240 mg	Progression-Free Survival (PFS) Per RECIST v1.1	2.86 Months

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Intervention model description

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Percentage of Participants With Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1)

Best Percentage Change From Baseline in Tumour Size

Duration of Response (DoR) Per RECIST v1.1

Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs

Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs

Number of Participants With Abnormal Physical Examination Findings Reported as TEAEs

Number of Participants With Abnormal Vital Signs Reported as TEAEs

Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

Overall Survival (OS)

Percentage of Participants With Disease Control (DC) Per RECIST v1.1

Progression-Free Survival (PFS) Per RECIST v1.1